[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 232
1. Tsubata C, Higuchi M, Takahashi M, Oie M, Tanaka Y, Gejyo F, Fujii M: PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line. Retrovirology; 2005;2:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein is essential for the interleukin 2 independent growth induction of a T-cell line.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia (ATL), whereas HTLV type 2 (HTLV-2), is not associated with ATL or any other leukemia.
  • [MeSH-minor] Binding Sites. Cell Line. Cell Proliferation. Humans. Leukemia-Lymphoma, Adult T-Cell / etiology. NF-kappa B / physiology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 2.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Mar;71(3):1956-62 [9032327.001]
  • [Cites] J Virol. 1996 Aug;70(8):5194-202 [8764028.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):643-54 [9482110.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11154-63 [10753922.001]
  • [Cites] Virology. 2000 May 25;271(1):142-54 [10814579.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Virol. 2003 Jun;77(12):6957-64 [12768014.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] Virology. 2004 Mar 1;320(1):52-62 [15003862.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Nature. 1983 Oct 6-12;305(5934):502-5 [6312323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(22):7006-9 [6316341.001]
  • [Cites] Science. 1985 Jul 5;229(4708):54-8 [2990037.001]
  • [Cites] EMBO J. 1986 Mar;5(3):561-5 [3011413.001]
  • [Cites] EMBO J. 1986 Nov;5(11):2883-8 [3024966.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1324-9 [2888190.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] J Virol. 1993 Mar;67(3):1211-7 [8437212.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6 [9326658.001]
  • (PMID = 16042787.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-2; 0 / NF-kappa B
  • [Other-IDs] NLM/ PMC1199618
  •  go-up   go-down


2. Jatiani SS, Baker SJ, Silverman LR, Reddy EP: Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer; 2010 Oct;1(10):979-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrations in these pathways, such as those caused by the recently identified JAK2(V617F) mutation and translocations of the JAK2 gene, are underlying causes of leukemias and other myeloproliferative disorders.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21442038.001).
  • [ISSN] 1947-6027
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL080666-06; United States / NHLBI NIH HHS / HL / R01 HL080666; United States / NHLBI NIH HHS / HL / R01 HL080666-06
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS260950; NLM/ PMC3063998
  • [Keywords] NOTNLM ; JAK / JAK2 inhibitors / STAT / cytokine receptor / myeloproliferative disorders
  •  go-up   go-down


3. Miyakoshi Y, Yoshioka H, Toyama Y, Suzuki Y, Shimizu H: The frequencies of micronuclei induced by cisplatin in newborn rat astrocytes are increased by 50-Hz, 7.5- and 10-mT electromagnetic fields. Environ Health Prev Med; 2005 May;10(3):138-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Epidemiological studies have suggested that exposure to environmental and occupational electromagnetic fields (EMFs) contribute to the induction of brain tumors, leukemia, and other neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1993 Jul;297(1):61-95 [7686274.001]
  • [Cites] Bioelectromagnetics. 2001;Suppl 5:S120-31 [11170122.001]
  • [Cites] Cancer. 1985 May 15;55(10):2303-l6 [3886121.001]
  • [Cites] FASEB J. 1992 Feb 1;6(3):853-60 [1740235.001]
  • [Cites] Annu Rev Biochem. 1992;61:809-60 [1497324.001]
  • [Cites] Tohoku J Exp Med. 1996 Nov;180(3):209-15 [9058505.001]
  • [Cites] Med Hypotheses. 1993 Jul;41(1):23-7 [8231974.001]
  • [Cites] Ann Intern Med. 1984 May;100(5):704-13 [6370067.001]
  • [Cites] Mutat Res. 1979 Mar;66(3):267-75 [440327.001]
  • [Cites] Cancer Lett. 1993 Jul 30;71(1-3):75-81 [8364901.001]
  • [Cites] Arch Toxicol. 1996;70(5):315-8 [8852704.001]
  • [Cites] Neurotoxicology. 1997;18(2):325-30 [9291482.001]
  • [Cites] J Cell Biochem. 2001;81(1):143-8 [11180404.001]
  • [Cites] Mutat Res. 1998 Apr;410(2):185-220 [9637236.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):941-3 [14997186.001]
  • [Cites] Life Sci. 1994;54(21):1531-43 [8196474.001]
  • [Cites] Mutat Res. 1970 May;9(5):527-49 [5424720.001]
  • [Cites] Mutat Res. 1983 Sep;123(1):61-118 [6888413.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2209-13 [193638.001]
  • [Cites] J Cell Biochem. 1993 Apr;51(4):394-403 [8098713.001]
  • [Cites] Ind Health. 1996;34(4):347-57 [8908845.001]
  • [Cites] J Cell Biochem. 1993 Apr;51(4):410-6 [8388394.001]
  • [Cites] Mutat Res. 1975 Feb;27(2):181-9 [1093011.001]
  • [Cites] Ann Intern Med. 1977 Jun;86(6):803-12 [326117.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Feb 1;162(3):166-76 [10652245.001]
  • [Cites] FASEB J. 1992 Oct;6(13):3177-85 [1397839.001]
  • [Cites] Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:84-7 [12019358.001]
  • [Cites] FASEB J. 1993 Feb 1;7(2):272-81 [8440406.001]
  • [Cites] Mutat Res. 1998 Aug;411(1):45-86 [9675241.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3627-33 [10446973.001]
  • [Cites] Bioelectromagnetics. 1999;20(3):133-60 [10194557.001]
  • [Cites] Neoplasma. 1984;31(6):655-9 [6395027.001]
  • [Cites] J Cell Biochem. 1993 Apr;51(4):381-6 [8496241.001]
  • [Cites] Mutagenesis. 2001 Nov;16(6):499-501 [11682641.001]
  • [Cites] Cancer Lett. 1995 Apr 14;90(2):207-14 [7736457.001]
  • [Cites] Ind Health. 1997 Apr;35(2):285-90 [9127563.001]
  • [Cites] Pharmacol Res. 2003 Jul;48(1):83-90 [12770519.001]
  • [Cites] Ind Health. 1999 Jan;37(1):95-102 [10052306.001]
  • [Cites] Epidemiol Rev. 1997;19(2):273-93 [9494788.001]
  • (PMID = 21432152.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2723253
  • [Keywords] NOTNLM ; astrocyte / cisplatin / electromagnetic fields / genotoxicity / micronucleus test
  •  go-up   go-down


Advertisement
4. Kang HJ, Yoo KH, Lee JW, Kim H, Lee SH, Sung KW, Park KD, Koo HH, Shin HY, Ahn HS: Double umbilical cord blood transplantation for children and adolescents. Ann Hematol; 2010 Oct;89(10):1035-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-one patients, including 44 acute leukemia, and 17 other hematologic diseases, received double UCBT.
  • Except one patient with persistent mixed chimerism of two units, other 49 patients showed dominancy of one unit and only the CFU-GM was significant factor influencing dominancy.
  • The event-free survival (EFS) of leukemia and other hematologic disease were 59% and 53%, respectively, and the EFS of acute leukemia patients who received transplant in first or second CR (68.6%) was significantly better than in those with advanced disease (22.2%) (P = 0.007).
  • However, engraftment and other results were not so satisfactory yet.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Fetal Blood / cytology. Hematologic Diseases / surgery. Leukemia / surgery


5. Huang ZF, Chen R, Li YZ, Chen GN, Chen XL, Feng SY, Jia PM: [Two-photon excitation fluorescence of 5-ALA induced PpIX in DHL cells]. Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Nov;28(11):2636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results indicate that two-photon fluorescence based on laser scanning microscope can be a useful technology for studying the kinetics of 5-ALA induced PpIX production in DHL cells and other leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19271507.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


6. Lackner H, Sovinz P, Benesch M, Smolle-Jüttner F, Mokry M, Schwinger W, Moser A, Urban C: Management of brain abscesses in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Mar;52(3):408-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of brain abscesses in children treated for acute lymphoblastic leukemia.
  • Brain abscesses in children with leukemia or other malignancies are rare and potentially fatal.
  • We report on four children who developed brain abscesses during treatment for acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Brain Abscess / complications. Brain Abscess / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989879.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


7. Detrich HW 3rd: Fluorescent proteins in zebrafish cell and developmental biology. Methods Cell Biol; 2008;85:219-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) analysis of kinesin motor function in the cleaving zebrafish embryo, (2) determination of the roles of semaphorins in axonal guidance, and (3) creation of transgenic models of leukemia and other cancers.
  • [MeSH-minor] Animals. Animals, Genetically Modified. Axons / physiology. Gene Expression Regulation, Developmental. Kinesin / genetics. Kinesin / metabolism. Leukemia-Lymphoma, Adult T-Cell. Models, Animal. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Transgenes

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155465.001).
  • [ISSN] 0091-679X
  • [Journal-full-title] Methods in cell biology
  • [ISO-abbreviation] Methods Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Zebrafish Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.1.- / Kinesin
  • [Number-of-references] 88
  •  go-up   go-down


8. Zhu Y, Xu W, Liu Q, Pan J, Qiu H, Wang R, Qiao C, Jiang Y, Zhang S, Fan L, Zhang J, Shen Y, Xue Y, Li J: [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct;25(5):579-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Abnormalities of chromosome 17 were analyzed in 73 patients with myeloid malignancies with CCAs showed by R banding and conventional karyotyping, including 21 acute myeloid leukemia (AML), 36 chronic myeloid leukemia (CML) and 16 myelodysplastic syndrome (MDS).
  • Five of the 6 cases with translocation of chromosomes 15 and 17 were acute promyelocytic leukemia, the other case was CML-BC.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics


9. Fan Y, Schreiber EM, Giorgianni A, Yalowich JC, Day BW: Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol; 2006 Jul;19(7):937-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etoposide is a widely used antineoplastic agent that has provided great success in the treatment of childhood leukemias and other malignancies.
  • Unfortunately, its use is associated with the increased risk of development of secondary acute myelogenous leukemias involving translocations at the MLL gene in chromosome band 11q23.
  • Previous studies showed that the phenoxyl radical of etoposide can be generated by myeloperoxidase (MPO), an enzyme prevalent in myeloid progenitor cells that can derive myelogenous leukemias.
  • We hypothesized that etoposide ortho-quinone could therefore form in myeloid progenitor cells and might be a contributor to the development of treatment-related secondary leukemias.
  • MPO-expressing human myeloid leukemia HL60 cells were treated with etoposide for 0.5 h in the presence and absence of the cosubstrate of MPO, hydrogen peroxide.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,4-BENZOQUINONE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Chem Res Toxicol. 2007 Jul;20(7):1067
  • (PMID = 16841962.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090787
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / DNA Adducts; 3T006GV98U / benzoquinone; 6PLQ3CP4P3 / Etoposide; EC 1.11.1.7 / Peroxidase; GAN16C9B8O / Glutathione
  •  go-up   go-down


10. Suzuki R, Ohtake S, Takeuchi J, Nagai M, Kodera Y, Hamaguchi M, Miyawaki S, Karasuno T, Shimodaira S, Ohno R, Nakamura S, Naoe T: The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. Int J Hematol; 2010 Mar;91(2):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
  • Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia.
  • Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed.
  • There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7).
  • These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells.
  • [MeSH-major] Antigens, CD56 / metabolism. Antigens, CD7 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2000 Nov;24(11):979-82 [11086183.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):532-44 [17916099.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1220-5 [8049437.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):66-72 [18283711.001]
  • [Cites] Br J Haematol. 1991 Jul;78(3):325-9 [1651754.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Haematologica. 2002 Mar;87(3):250-6 [11869936.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1783-9 [15223636.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2863-92 [9376567.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1135-40 [12414342.001]
  • [Cites] J Exp Med. 1994 Aug 1;180(2):569-76 [7519241.001]
  • [Cites] Int J Hematol. 1991 Oct;54(5):395-403 [1721853.001]
  • [Cites] Blood. 1994 Jul 1;84(1):244-55 [7517211.001]
  • [Cites] Blood. 2000 Aug 1;96(3):870-7 [10910899.001]
  • [Cites] Blood. 2003 May 1;101(9):3444-50 [12506032.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2405-11 [11001891.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3538-46 [7540065.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1161-4 [11480556.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2465-70 [9310499.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1564-70 [7522295.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1643-8 [9269784.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):293-7 [10458245.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):43-8 [14630079.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Leukemia. 1994 May;8(5):823-6 [7514247.001]
  • [Cites] Leuk Lymphoma. 1995 Oct;19(3-4):295-300 [8535222.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):223-34 [16213152.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):425-31 [16400344.001]
  • [Cites] Br J Haematol. 2008 Apr;141(1):129-31 [18279455.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1295-300 [10715300.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1284-93 [16160469.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):482-9 [12841387.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4629-36 [15231675.001]
  • (PMID = 20111912.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S: The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol; 2007 Aug;27(15):5499-513
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sorafenib is a multikinase inhibitor that induces apoptosis in human leukemia and other malignant cells.
  • Notably, treatment with sorafenib induced endoplasmic reticulum (ER) stress in human leukemia cells (U937) manifested by immediate cytosolic-calcium mobilization, GADD153 and GADD34 protein induction, PKR-like ER kinase (PERK) and eukaryotic initiation factor 2alpha (eIF2alpha) phosphorylation, XBP1 splicing, and a general reduction in protein synthesis as assessed by [35S]methionine incorporation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6388S-92S [15448036.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9695-704 [15509775.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 [7682708.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4327-34 [9020152.001]
  • [Cites] Neurochem Int. 2006 Jun;48(8):696-702 [16481070.001]
  • [Cites] Clin Genitourin Cancer. 2006 Mar;4(4):246-8 [16729906.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] Exp Cell Res. 2006 Jul 15;312(12):2347-57 [16701639.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33078-86 [16945918.001]
  • [Cites] Nature. 2004 Aug 5;430(7000):694-9 [15258597.001]
  • [Cites] Cell Death Differ. 1999 Nov;6(11):1081-6 [10578177.001]
  • [Cites] Mol Cell. 2000 May;5(5):897-904 [10882126.001]
  • [Cites] Annu Rev Immunol. 1998;16:395-419 [9597135.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):271-4 [9930704.001]
  • [Cites] Nature. 2005 Feb 3;433(7025):477-80 [15690031.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2412-21 [15781657.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2422-32 [15781658.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14189-202 [15684420.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):576-83 [15825194.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):541-6 [15818413.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):23122-9 [15826945.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):23194-202 [15849362.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6780-8 [16061660.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5493-501 [16176978.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 7;97(23):1781-5 [16333034.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11510-9 [16357160.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1611-9 [16452220.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1702-11 [16452230.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):374-84 [16397578.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):363-73 [16397583.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11923-32 [16446371.001]
  • [Cites] Science. 2006 Apr 28;312(5773):572-6 [16645094.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1756-63 [10961874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5106-15 [11431348.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1165-76 [11430820.001]
  • [Cites] Cell. 2001 Dec 28;107(7):881-91 [11779464.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Nature. 2002 Jan 3;415(6867):92-6 [11780124.001]
  • [Cites] Trends Cardiovasc Med. 2002 Feb;12(2):57-62 [11852251.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):18077-83 [11877419.001]
  • [Cites] Genes Dev. 2002 Jun 1;16(11):1345-55 [12050113.001]
  • [Cites] Exp Cell Res. 2002 Jul 1;277(1):31-47 [12061815.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7405-16 [12370288.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1383-8 [12438433.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1180-7 [12606582.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1573-5 [12824288.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6231-42 [13679862.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):169-79 [14713949.001]
  • [Cites] Trends Cell Biol. 2004 Jan;14(1):20-8 [14729177.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2025-40 [14966282.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1364-76 [14647418.001]
  • [Cites] Int Immunopharmacol. 2004 Apr;4(4):475-93 [15099526.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):347-56 [15123740.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Oncogene. 2004 Aug 19;23(37):6292-8 [15208680.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Oct;287(4):C817-33 [15355853.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40755-61 [15262979.001]
  • (PMID = 17548474.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100866; United States / NCI NIH HHS / CA / R01 CA063753; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA 63753; United States / NCI NIH HHS / CA / CA 100866; United States / NCI NIH HHS / CA / CA 93738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / DNA-Binding Proteins; 0 / Eukaryotic Initiation Factor-2; 0 / Nuclear Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Reactive Oxygen Species; 0 / Transcription Factors; 0 / regulatory factor X transcription factors; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.- / PERK kinase; EC 2.7.11.1 / eIF-2 Kinase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.22.- / CASP4 protein, human; EC 3.4.22.- / Caspase 2; EC 3.4.22.- / Caspases, Initiator
  • [Other-IDs] NLM/ PMC1952105
  •  go-up   go-down


12. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC: A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood; 2005 Mar 15;105(6):2504-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic lymphocytic leukemia (CLL) is an incurable adult leukemia characterized by disrupted apoptosis.
  • Moreover, unlike the great majority of therapeutic agents used to treat leukemia or other forms of cancer, OSU03012 induces cell death entirely independent of bcl-2 expression.
  • [MeSH-major] Apoptosis / drug effects. Cell Transformation, Neoplastic / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, B-Cell / metabolism. Pyrazoles / pharmacology. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15454489.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA81534-02; United States / NCI NIH HHS / CA / P01 CA95426-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / OSU 03012; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 3.4.22.- / Caspases
  •  go-up   go-down


13. Sethi G, Ahn KS, Aggarwal BB: Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res; 2008 Jun;6(6):1059-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, our results indicate that the anticancer and antiinflammatory activities previously assigned to TQ may be mediated in part through the suppression of the NF-kappa B activation pathway, as shown here, and thus may have potential in treatment of myeloid leukemia and other cancers.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567808.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA016672-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Benzoquinones; 0 / Carcinogens; 0 / I-kappa B Proteins; 0 / Inflammation Mediators; 0 / NF-kappa B; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 139874-52-5 / NF-kappaB inhibitor alpha; 490-91-5 / thymoquinone; 9007-49-2 / DNA; EC 2.7.11.10 / I-kappa B Kinase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


14. Qian XF, Shen YF, Zhang SJ, Li JY: [Mutation of tet2 gene and malignant blood disease]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):1096-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, the relation of tet2 mutation with myeloproliferative neoplasm, systemic mastocytosis, myelodysplastic syndrome, acute myeloid leukemia and other malignant blood diseases are summarized.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723337.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human
  •  go-up   go-down


15. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A; 2005 Jan 25;102(4):1104-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
  • To explore the genetic abnormalities that cooperate with AML1-ETO (AE) fusion gene to cause acute myeloid leukemia (AML) with t(8;21), we screened a number of candidate genes and identified 11 types of mutations in C-KIT gene (mC-KIT), including 6 previously undescribed ones among 26 of 54 (48.1%) cases with t(8;21).
  • This may lead to an alternative way of C-KIT activation and may explain the significantly higher C-KIT expression in 81.3% of patients with t(8;21) than in patients with other leukemias.
  • These data strongly suggest that t(8;21) AML follows a stepwise model in leukemogenesis, i.e., AE represents the first, fundamental genetic hit to initiate the disease, whereas activation of the C-KIT pathway may be a second but also crucial hit for the development of a full-blown leukemia.
  • Gleevec also exerted a synergic effect in apoptosis induction with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / genetics. Mutation. Oncogene Proteins, Fusion / genetics. Piperazines / pharmacology. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / pharmacology. Transcription Factors / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2003 Feb;13(2):287-93 [12566407.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1359-68 [11516096.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):775-7 [12780793.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3306-11 [12843079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11 [12881486.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5646-57 [12944913.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4369-76 [12946995.001]
  • [Cites] Blood. 2004 May 15;103(10):3644-54 [14726395.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4255-62 [15156181.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9 [15477599.001]
  • [Cites] Blood. 1993 Aug 1;82(3):712-5 [8338940.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3638-42 [7687925.001]
  • [Cites] Leukemia. 1994 Feb;8(2):258-63 [7508533.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1769-80 [7535588.001]
  • [Cites] Leukemia. 1996 Feb;10(2):288-96 [8637238.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4789-96 [8639850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11895-900 [8876234.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1701-10 [10208431.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3635-44 [10207087.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14882-7 [10611307.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Blood. 2000 Jul 15;96(2):655-63 [10887131.001]
  • [Cites] Blood. 2000 Jul 1;96(1):288-96 [10891464.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2108-15 [10979955.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40282-7 [11032826.001]
  • [Cites] Biochem J. 2001 Mar 15;354(Pt 3):481-4 [11237851.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5577-90 [11463839.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6470-83 [11533236.001]
  • [Cites] Blood. 2002 Jan 1;99(1):15-23 [11756147.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):744-57 [11886377.001]
  • [Cites] Hematol J. 2001;2(5):330-40 [11920269.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5506-17 [12101243.001]
  • [Cites] Hematol J. 2002;3(3):157-63 [12111653.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1115-24 [12481435.001]
  • [Cites] Blood. 2003 Jan 1;101(1):270-7 [12393465.001]
  • [Cites] Blood. 2003 Jan 15;101(2):624-32 [12393523.001]
  • [Cites] Leukemia. 2003 Feb;17(2):471-2 [12592353.001]
  • (PMID = 15650049.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Transcription Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC545849
  •  go-up   go-down


16. Bartley AN, Nelson CL, Nelson DH, Fuchs DA: Disseminated extramedullary myeloid tumor of the gallbladder without involvement of the bone marrow. Am J Hematol; 2007 Jan;82(1):65-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They usually arise concurrently with a diagnosis of acute myeloid leukemia, chronic myeloid leukemia, or other myeloproliferative disorders.
  • They may also indicate relapsing disease in a patient with a prior history of leukemia or myeloproliferative disorder.
  • She subsequently developed respiratory failure; pre- and postmortem bone marrow studies were negative for leukemia by morphology, flow cytometry, and karyotypic analysis.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16947321.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; EC 1.11.1.7 / Peroxidase; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


17. Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA: Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet; 2006 Mar;165(2):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia and constitutional trisomy 21.
  • The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four.
  • Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers.
  • The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7).
  • The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare.
  • [MeSH-major] Down Syndrome. Leukemia, Promyelocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527614.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res; 2005 May;29(5):503-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological identification of immunogenic antigens in acute monocytic leukemia.
  • In order to improve disease-free survival and potentially a cure, it is necessary to identify more potent leukemia antigen.
  • Here, we defined the acute monocytic leukemia-associated antigen (LAA) recognized by the humoral immune system for the first time.
  • We have applied the method of serologic analysis of recombinant cDNA expression library (SEREX) on acute monocytic leukemia (FAB M5), followed by DNA sequencing and analyzing of positive clones.
  • Then, the reactivity of normal and other leukemia sera with positive clones were performed.
  • Thirty-five distinct novel antigens reactive with autologous IgG were identified by SEREX analysis on an acute monocytic leukemia patient and were characterized according to cDNA sequence and the reactivity with allogeneic sera.
  • Twenty of the 35 antigens identified in this study were recognized by IgG antibodies in normal sera, and the remaining 15 were recognized exclusively by sera from allogeneic leukemia patients but not by normal donor sera, suggested that the immune response to these 15 antigens are leukemia related.
  • The 15 immunogenic antigens detected by immune responses in the autologous host facilitate the identification of epitopes recognized by antigen-specific cytotoxic T lymphocytes (CTL) and are potential candidates for diagnosis and immunotherapy in acute myeloid leukemia (AML).
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Immunoglobulin G / immunology. Leukemia, Monocytic, Acute / immunology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755502.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G
  •  go-up   go-down


19. Wang J, Li L, Cang H, Shi G, Yi J: NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res; 2008 Mar;32(3):429-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells.
  • We have previously demonstrated that an acute promyelocytic leukemia (APL)-derived cell line NB4 exhibited a relatively higher basal level of reactive oxygen species (ROS) than other leukemia cell lines, which is one of the mechanisms determining a higher apoptotic susceptibility of NB4 cells to arsenic trioxide (ATO)-induced apoptosis.
  • [MeSH-major] Arsenicals / pharmacology. Leukemia, Promyelocytic, Acute / metabolism. NADPH Oxidase / metabolism. Oxides / pharmacology. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804067.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 0 / Reactive Oxygen Species; EC 1.6.3.1 / NADPH Oxidase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


20. Dogan E, Erkoc R, Sayarlioglu H, Alici S, Dilek I, Alici O: Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report. Adv Ther; 2005 Sep-Oct;22(5):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no reason other than leukemia-such as infection, circulatory failure, or drug use-for the development of severe LA.
  • [MeSH-major] Acidosis, Lactic / etiology. Leukemia, Promyelocytic, Acute / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418152.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Adewale AJ, Dinu I, Potter JD, Liu Q, Yasui Y: Pathway analysis of microarray data via regression. J Comput Biol; 2008 Apr;15(3):269-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Applications of the proposed method are illustrated with two real pathway-analysis examples: one evaluating relapse-associated gene expression involving a matched-pair binary phenotype in children with acute lymphoblastic leukemia; and the other investigating gene expression in breast cancer tissues in relation to patients' survival (a censored survival phenotype).
  • [MeSH-minor] Breast Neoplasms / genetics. Child. Demography. Female. Humans. Phenotype. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proportional Hazards Models. Recurrence. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331198.001).
  • [ISSN] 1066-5277
  • [Journal-full-title] Journal of computational biology : a journal of computational molecular cell biology
  • [ISO-abbreviation] J. Comput. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Lehtinen M, Ogmundsdottir HM, Bloigu A, Hakulinen T, Hemminki E, Gudnadottir M, Kjartansdottir A, Paavonen J, Pukkala E, Tulinius H, Lehtinen T, Koskela P: Associations between three types of maternal bacterial infection and risk of leukemia in the offspring. Am J Epidemiol; 2005 Oct 1;162(7):662-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between three types of maternal bacterial infection and risk of leukemia in the offspring.
  • A case-control study was nested within two maternity cohorts with a total of 7 million years of follow-up for assessment of the role of bacterial infections in childhood leukemia.
  • First-trimester serum samples were retrieved from mothers of 341 acute lymphoblastic leukemia cases and 61 other leukemia cases and from 1,212 control mothers.
  • In Iceland, H. pylori immunoglobulin G was associated with increased risk of childhood leukemia in offspring (OR = 2.8, 95% confidence interval: 1.1, 6.9).
  • [MeSH-major] Chlamydia Infections / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori. Pneumonia, Mycoplasma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Pregnancy Complications, Infectious / epidemiology. Pregnancy Complications, Infectious / microbiology

  • MedlinePlus Health Information. consumer health - Chlamydia Infections.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120707.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


23. Hadi E, Sharony R, Goldberg-Bittman L, Biron-Shental T, Fejgin M, Amiel A: Telomere aggregates in trisomy 21 amniocytes. Cancer Genet Cytogenet; 2009 Nov;195(1):23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Down syndrome carries an increased risk of developing acute leukemia and other malignancies.
  • The TAs found in trisomy 21 amniocytes apparently represent an additional parameter that reflects the high genetic instability of this syndrome and its recognized predisposition to develop leukemia and other malignancies.

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837264.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mitiushova EV, Aksenov ND, Marakhova II: [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. Tsitologiia; 2010;52(2):184-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131].
  • In this study, we examined the possible role of JAK/STAT signaling pathway in regulation of proliferation of chronic leukemia cells K562.
  • Thus, our findings indicate a preferential role for STAT5 (not constitutively active STAT3) in proliferation of leukemia to other JAK drugs which stimulate apoptosis and decrease proliferation, WHI-P131 prevents K562 cells growth by arresting in G2/M phases of cell cycle.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20352702.001).
  • [ISSN] 0041-3771
  • [Journal-full-title] Tsitologiia
  • [ISO-abbreviation] Tsitologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Quinazolines; 0 / STAT5 Transcription Factor; 0 / WHI P131
  •  go-up   go-down


25. Sato K, Eizumi K, Fukaya T, Fujita S, Sato Y, Takagi H, Yamamoto M, Yamashita N, Hijikata A, Kitamura H, Ohara O, Yamasaki S, Saito T, Sato K: Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease. Blood; 2009 May 7;113(19):4780-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic graft-versus-host disease (cGVHD) is a limiting factor in allogeneic hematopoietic stem cell transplantation (alloHSCT) for the treatment of leukemia and other malignancies.
  • CD49(+)CD200R3(+) cells showed similarities in phenotype and function to BM-DC(regs), which formally distinguishes them from other leukocytes, suggesting that they are the natural counterpart of BM-DC(regs).

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228924.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CD200 receptor, mouse; 0 / DNA-Binding Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Rag2 protein, mouse
  •  go-up   go-down


26. Wang J, Hasui K, Utsunomiya A, Jia X, Matsuyama T, Murata F: Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL. J Clin Exp Hematop; 2008 Apr;48(1):1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.
  • Proliferation, apoptosis and p53 protein expression in adult T-cell leukemia (ATL) cells were investigated.
  • Twenty peripheral blood tissue specimens (PBTS) comprising 7 cases of acute type ATL, 7 cases of chronic type ATL and 6 other leukemias were examined by means of antigen retrieval and the polymer method employing anti-Ki67 antigen (MIB-1), anti-cleaved caspase-3, anti-single stranded DNA and three kinds of anti-p53 protein antibodies including DO7.
  • Most acute and chronic cases of ATL included more than 10% MIB-1-positive proliferating leukemia cells and more than 1% cleaved caspase-3-positive apoptotic cells.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434687.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


27. Brueckner B, Kuck D, Lyko F: DNA methyltransferase inhibitors for cancer therapy. Cancer J; 2007 Jan-Feb;13(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical concepts for epigenetic therapies are currently being developed by using azanucleosides for the treatment of leukemias and other tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 10157 .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464242.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  • [Number-of-references] 52
  •  go-up   go-down


28. Datta K, Ghosh RK, Ghosh SM: Serious neutropenia following etanercept administration in a 62 years female patient of rheumatoid arthritis. J Assoc Physicians India; 2010 Oct;58:643-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other marrow components were normal.
  • Recently, there are some reports of leukemia and other hematological malignancies associated with the use of etanercept and in those conditions neutropenia could be the first manifestation.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Etanercept .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21510121.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; OP401G7OJC / Etanercept; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


29. Middelhof CA, Loudon WG, Muhonen MD, Xavier C, Greene CS Jr: Improved survival in central nervous system aspergillosis: a series of immunocompromised children with leukemia undergoing stereotactic resection of aspergillomas. Report of four cases. J Neurosurg; 2005 Oct;103(4 Suppl):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival in central nervous system aspergillosis: a series of immunocompromised children with leukemia undergoing stereotactic resection of aspergillomas. Report of four cases.
  • From their literature review, the authors concluded that children contracting CNS aspergillosis while undergoing systemic chemotherapy for leukemias represent a particularly unfortunate prognostic group.
  • The authors present a series of four immunosuppressed patients whose course of treatment for leukemia was complicated by CNS Aspergillus sp. abscesses.
  • At 2- to 4-year follow ups, one patient has died of leukemia and the other three continue to thrive without evidence of recurrent aspergillosis.
  • [MeSH-major] Brain Diseases / mortality. Brain Diseases / surgery. Immunocompromised Host. Leukemia / drug therapy. Neuroaspergillosis / mortality. Neuroaspergillosis / surgery. Stereotaxic Techniques


30. Ferrara F: Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother; 2010 Mar;11(4):587-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: what are the treatment options?
  • IMPORTANCE OF THE FIELD: Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology.
  • TAKE HOME MESSAGE: To date, the therapy of APL is the most successful example of differentiation therapy and its scientific history can serve as a model for subsequent development of similar treatments in other leukemias and cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163270.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 75
  •  go-up   go-down


31. Sarvis JA, Auge BK: Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia. Urology; 2009 May;73(5):1163.e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
  • Myeloid sarcoma involving the genitourinary system is a rare complication associated with acute myelogenous leukemia or other myeloproliferative disorders.
  • We report the second known case of myeloid sarcoma involving the epididymis in a patient with a history of acute myelogenous leukemia.
  • [MeSH-major] Epididymis / pathology. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis. Testicular Neoplasms / diagnosis


32. Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A: Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica; 2005 Nov;90 Suppl:ECR23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report transient severe acute thrombocytopenia after rituximab infusion in two patients with, one hairy cell leukemia the other with mantle cell lymphomay.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Bone Marrow / pathology. Humans. Leukemia, Hairy Cell / blood. Leukemia, Hairy Cell / drug therapy. Leukemia, Hairy Cell / pathology. Lymphoma, Mantle-Cell / blood. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266914.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Kolb HJ: Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood; 2008 Dec 1;112(12):4371-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effects of transplantation and donor lymphocytes.
  • Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even in advanced stages.
  • Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) effect, but the beneficial effect is limited by graft-versus-host disease (GVHD).
  • Durable responses may be the result of the elimination of leukemia stem cells or the establishment of a durable immune control on their progeny.
  • Recently, we have learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for the effective treatment of leukemia and other malignancies.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Lymphocyte Transfusion. Lymphocytes / immunology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Blood Donors. Graft vs Host Disease / etiology. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Graft vs Host Reaction. Humans. Imatinib Mesylate. Immune Tolerance / immunology. Immunotherapy, Adoptive / adverse effects. Immunotherapy, Adoptive / methods. Leukemia / immunology. Leukemia / mortality. Leukemia / prevention & control. Leukemia / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Transplantation Immunology / physiology. Tumor Escape / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029455.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 169
  •  go-up   go-down


34. Chan FH, Carl D, Lyckholm LJ: Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature. Case Rep Med; 2009;2009:534561
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma and leukemia are among other clinical situations where lactic acidosis has been reported.
  • Prompt diagnosis and treatment of underlying lymphoma or leukemia remains the only way to achieve complete resolution of lactic acidosis in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Ther. 2007 May-Jun;24(3):505-9 [17660158.001]
  • [Cites] Chest. 2000 Jan;117(1):260-7 [10631227.001]
  • [Cites] Mayo Clin Proc. 2006 Nov;81(11):1505-6; author reply 1506 [17120408.001]
  • [Cites] Adv Ther. 2005 Sep-Oct;22(5):443-6 [16418152.001]
  • [Cites] J Intensive Care Med. 2005 Sep-Oct;20(5):255-71 [16145217.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):281-3 [15621814.001]
  • [Cites] Int J Hematol. 2004 Dec;80(5):428-31 [15646654.001]
  • [Cites] N Engl J Med. 1964 Feb 6;270:274-8 [14074652.001]
  • [Cites] Lung Cancer. 1998 Dec;22(3):251-4 [10048478.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):315-30 [9387092.001]
  • [Cites] Am Surg. 1997 Nov;63(11):951-3 [9358778.001]
  • [Cites] Ann Hematol. 1996 Feb;72(2):97-9 [8597616.001]
  • [Cites] Nephron. 1994;66(3):258-61 [8190176.001]
  • [Cites] Leukemia. 1994 Jun;8(6):1065-6 [8207979.001]
  • [Cites] Chest. 1993 Sep;104(3):913-8 [8396003.001]
  • [Cites] Am J Med. 1991 Aug;91(2):197-8 [1651052.001]
  • [Cites] Crit Care Med. 1991 Nov;19(11):1352-6 [1935152.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 7;80(13):1077-8 [3411621.001]
  • [Cites] South Med J. 1988 Apr;81(4):533-6 [3282319.001]
  • [Cites] Minn Med. 1986 Sep;69(9):511-4 [3020387.001]
  • [Cites] Am J Physiol. 1985 Nov;249(5 Pt 2):F630-5 [2998202.001]
  • [Cites] Am J Med. 1989 Jul;87(1):7-14 [2741982.001]
  • [Cites] Mil Med. 1985 Apr;150(4):206-8 [3925375.001]
  • [Cites] Aust N Z J Med. 1983 Apr;13(2):179-80 [6577838.001]
  • [Cites] N Engl J Med. 1980 Jul 3;303(1):15-7 [7374729.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):2026-9 [6261933.001]
  • [Cites] Am J Hematol. 1978;4(4):359-65 [362908.001]
  • [Cites] Am J Med. 1974 Feb;56(2):162-8 [4812073.001]
  • [Cites] Gut. 1975 Feb;16(2):144-9 [1126664.001]
  • [Cites] J Clin Invest. 1971 Mar;50(3):700-6 [5545127.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1341-2 [12153006.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2237-46 [11745277.001]
  • [Cites] Nephron. 2001 Jul;88(3):276-7 [11423762.001]
  • [Cites] Chest. 2000 Sep;118(3):882-4 [10988226.001]
  • [Cites] Medicine (Baltimore). 2007 Jul;86(4):225-32 [17632264.001]
  • (PMID = 20069124.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2804112
  •  go-up   go-down


35. Fuchs O: [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases]. Cas Lek Cesk; 2006;145(8):619-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
  • EVI1 was detected in hematopoietic cells in retrovirus-induced myeloid leukemias in mice and several reports documented EVI1 expression in human myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
  • EVI1 is abnormally expressed in human myeloid leukemias that are associated with the t(3;3)(q21;q26), t(3;21)(q26;q22), inv(3)(q21q26) and other chromosomal rearrangements.
  • Knockdown of EVI1 function by small interference RNA increases the sensitivity of malignant cells to TGFbeta-mediated or other inducer-mediated apoptosis.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Myelodysplastic Syndromes / genetics. Neoplasms / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics


36. Mehlman MA: Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industries. Part XXX: Causal relationship between chronic myelogenous leukemia and benzene-containing solvents. Ann N Y Acad Sci; 2006 Sep;1076:110-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industries. Part XXX: Causal relationship between chronic myelogenous leukemia and benzene-containing solvents.
  • Both animal studies and human epidemiological studies have shown statistically significant increases of leukemia and other lymphohematopoietic cancers in workers exposed to benzene.
  • The most common leukemia that has been associated with benzene exposure, also called benzene poisoning, is acute myelocytic leukemia (AML).
  • A review of the epidemiological literature on workers exposed to benzene or benzene-containing solvents and products shows, without question, that this exposure is significantly related to other types of leukemia and lymphoma.
  • In this article, we review the literature on the relationship between benzene exposure and chronic myelogenous leukemia (CML) and find that benzene and benzene-containing products are significantly related to morbidity and mortality from CML.
  • [MeSH-major] Benzene / toxicity. Carcinogens / toxicity. Industry. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Petroleum

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119196.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Petroleum; 0 / Solvents; J64922108F / Benzene
  • [Number-of-references] 66
  •  go-up   go-down


37. Liu XH, Ma XH, Tan CY, Jiang YY, Go ML, Low BC, Chen YZ: Virtual screening of Abl inhibitors from large compound libraries by support vector machines. J Chem Inf Model; 2009 Sep;49(9):2101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Successes of several marketed and clinical trial Abl inhibitors against leukemia and other cancers and appearances of reduced efficacies and drug resistances have led to significant interest in and efforts for developing new Abl inhibitors.
  • It is desirable to explore other in silico methods capable of searching large compound libraries at high yields and reduced false-hit rates.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689138.001).
  • [ISSN] 1549-960X
  • [Journal-full-title] Journal of chemical information and modeling
  • [ISO-abbreviation] J Chem Inf Model
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  •  go-up   go-down


38. Soria EA, Eynard AR, Quiroga PL, Bongiovanni GA: Differential effects of quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines. Life Sci; 2007 Oct 13;81(17-18):1397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic has been proposed as a chemotherapeutic agent for leukemia and other solid tumors.

  • Hazardous Substances Data Bank. QUERCETIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931660.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenites; 0 / Free Radicals; 0 / Silymarin; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite; 9IKM0I5T1E / Quercetin; EC 2.3.2.2 / gamma-Glutamyltransferase; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


39. Sommers CH, Schiestl RH: Effect of benzene and its closed ring metabolites on intrachromosomal recombination in Saccharomyces cerevisiae. Mutat Res; 2006 Jan 29;593(1-2):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benzene is associated with leukemia and other blood related disorders in humans.
  • Interestingly, p-benzoquinone induced DEL recombination at a dose 300-fold lower than any of the other metabolites, suggesting that it might be responsible for much of benzene's genotoxicity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BENZENE .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154601.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / Mutagens; J64922108F / Benzene
  •  go-up   go-down


40. Müller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister SM, Schütt B, Reize P, Greil J, Handgretinger R, Rudert M: Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia; 2008 Nov;22(11):2054-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteonecrosis is a frequent complication after treatment for childhood leukemia and other steroid-based therapies.

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719618.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


41. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.


42. Moon H, Huh J, Cho MS, Chi H, Chung WS: A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology. Korean J Lab Med; 2007 Aug;27(4):253-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology.
  • The differential diagnosis of acute lymphoblastic leukemia (ALL) from other small round blue cell tumors in children is very important for proper treatment, but sometimes difficult.
  • CD45 is expressed on almost all-human leukocytes and not expressed on other small round blue cell tumors.
  • The cytogenetic study showed normal karyotype but amplification of MLL (myeloid/lymphoid or mixed lineage leukemia) gene was suggestive in the fluorescent in situ hybridization.
  • The patient received the standard chemotherapy for acute lymphoblastic leukemia and reached complete remission.
  • [MeSH-major] Antigens, CD19 / analysis. Antigens, CD45 / analysis. Bone Marrow / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094585.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


43. Rosati A, Ammirante M, Gentilella A, Basile A, Festa M, Pascale M, Marzullo L, Belisario MA, Tosco A, Franceschelli S, Moltedo O, Pagliuca G, Lerose R, Turco MC: Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol; 2007;39(7-8):1337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, cell transformation induces a stress response, that is overcome, in neoplastic cells, by alterations in apoptosis modulators; on the other hand, antineoplastic therapies largely trigger the apoptosis stress pathway, whose impairment results in resistance.
  • This assists polypeptide folding, can mediate protein delivery to proteasome and is able to modulate apoptosis by interfering with cytochrome c release, apoptosome assembly and other events in the death process.
  • It has been recently shown that, in human primary lymphoid and myeloblastic leukemias and other neoplastic cell types, BAG3 expression sustains cell survival and underlies resistance to therapy, through downmodulation of apoptosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493862.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / BAG3 protein, human; 0 / HSP70 Heat-Shock Proteins
  • [Number-of-references] 46
  •  go-up   go-down


44. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S: Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer; 2006 Jun 15;106(12):2645-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of alemtuzumab in patients with CD52-positive acute leukemia.
  • BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic leukemia and other CD52-positive lymphoproliferative disorders.
  • Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • METHODS: Fifteen patients with CD52-positive (> or = 20%), recurrent or refractory acute leukemia (9 patients with AML and 6 patients with ALL) received alemtuzumab at a dose of 30 mg intravenously given 3 times a week (dose escalation during Week 1) for a total of 4 to 12 weeks.
  • CONCLUSIONS: Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute leukemia.
  • An evaluation in patients with a better prognosis, in combination with other agents or as part of consolidation therapy, is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688777.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


45. Betz BL, Hess JL: Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med; 2010 Oct;134(10):1427-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia diagnosis in the 21st century.
  • CONTEXT: Rapid advances in understanding the molecular biology of acute myeloid leukemia are transforming the approach to diagnosis, prognostication, and treatment of these cases.
  • OBJECTIVE: To briefly review the current state of AML classification with a particular emphasis on the role of molecular studies and their impact on the management of acute myeloid leukemia and other malignancies.
  • [MeSH-major] Chromosome Aberrations / classification. Leukemia, Myeloid, Acute / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923295.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / DNA Transposable Elements; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


46. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A: Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res; 2010 Sep;34(9):1224-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
  • Leukemia cell lines were treated with eltrombopag or thrombopoietin and their proliferative response was determined.
  • The addition of other cytokines, such as G-CSF, Epo or Tpo, did not affect the decrease in proliferation.
  • These findings suggest that eltrombopag does not enhance, but rather inhibits, proliferation of leukemia cell lines in vitro.
  • [MeSH-major] Benzoates / pharmacology. Hydrazines / pharmacology. Leukemia / pathology. Leukemia, Myeloid, Acute / pathology. Lymphoma / pathology. Pyrazoles / pharmacology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20202683.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / DNA Primers; 0 / Hydrazines; 0 / Pyrazoles; 0 / eltrombopag
  •  go-up   go-down


47. Rampal R, Luther KB, Haltiwanger RS: Notch signaling in normal and disease States: possible therapies related to glycosylation. Curr Mol Med; 2007 Jun;7(4):427-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, mutations of the Notch protein and components of its signaling pathway have been implicated in an array of human diseases (T-cell leukemia and other cancers, Multiple Sclerosis, CADASIL, Alagille Syndrome, Spondylocostal Dysostosis).

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584081.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM061126; United States / NIGMS NIH HHS / GM / GM61126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Receptors, Notch; 0 / delta protein; 134324-36-0 / Serrate proteins; 3713-31-3 / Fucose; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.- / N-Acetylglucosaminyltransferases
  •  go-up   go-down


48. Chen BA, Dong WM, Ding JH, Sun XM, Deng XJ, Zhang Y, Bi YZ, Zhao G, Gao C, Sun YY, Wang J, Cheng J, Schmitt M, Schmitt A: [Selective elimination of alloreactive donor lymphocytes by using TBI and cyclophosphamide]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female (BALB/c x C57BL/6) F1 mice (H-2(d/b)) as recipients received (60)Co gamma-ray sublethal TBI of 4 Gy on day 0 followed by being inoculated with P388D1 leukemia cell line on day 1, injection of allogeneic splenocytes from C57BL/6 male mice (H-2(b)) was carried out for induction of graft-vs-leukemia (GVL) effect prior to stem cell transplantation (SCT), intraperitoneally injection of cyclophosphamide (Cy) (200 mg/kg) and TBI (9 Gy) was given on day 6.
  • The results showed that recipients had no occurrence of leukemia and GVHD through selective elimination of alloreactive donor lymphocytes by Cy and TBI, survived more than 210 days, the complete-donor chimerism occurred on day 21 after transplantation.
  • Control mice died of GVHD, leukemia or other death-related-transplantation within 20 to 36 days (P<0.01).

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493342.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


49. Ruiz-Argüelles GJ, Morales-Toquero A, Cruz-Domínguez G, Reyes-Núñez V, López-Martínez B, Ruiz-Delgado GJ, Garcés-Eisele J: HFE-codon 63/282 (H63D/C282Y) gene variants in Mexican Mestizos are not risk factors for leukemia. Arch Med Res; 2006 Jan;37(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HFE-codon 63/282 (H63D/C282Y) gene variants in Mexican Mestizos are not risk factors for leukemia.
  • BACKGROUND: In some Caucasian populations it has been found that the C282Y hemochromatosis (HFE) gene mutation is a risk factor for the development of leukemia and other malignancies.
  • RESULTS: In the group of patients with leukemia we found a heterozygote for the C282Y mutation, seven heterozygotes for the H63D mutation, a double heterozygote for the H63D / C282Y mutation and 41 normal homozygotes.
  • CONCLUSIONS: These HFE gene mutations are not risk factors for the development of leukemia in Mexican mestizos.
  • [MeSH-major] Amino Acid Substitution. Codon / genetics. Histocompatibility Antigens Class I / genetics. Leukemia / genetics. Lupus Erythematosus, Systemic / genetics. Membrane Proteins / genetics. Point Mutation

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314188.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins
  •  go-up   go-down


50. Ambrose LR, Morel AS, Warrens AN: Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood; 2009 Oct 1;114(14):3052-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a climate of increased use of alemtuzumab in leukemia and other disease states, as well as in transplantation, these data highlight the need for increased vigilance of emerging neutropenia in patients treated with alemtuzumab.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638623.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / RNA, Messenger; 3A189DH42V / alemtuzumab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


51. Wang C, Chen Z, Li Z, Cen J: The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res; 2010 Aug;34(8):1083-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
  • The frequency of extramedullary infiltration (EMI) in acute myeloblastic leukemia (AML) is reported up to 40% and most prevalent in myelo-monoblastic and monoblastic subtypes of AML (M4 and M5 according to FAB classification).
  • To explore mechanism underlying EMI, we analyzed SHI-1 cells, a highly invasive human acute monocytic leukemia cell line, and found their strong expression of matrix metalloproteinase 2 (MMP-2), membrane type 1 MMP (MT1-MMP) and tissue inhibitor of metalloproteinase 2 (TIMP-2).
  • SHI-1 cells showed higher invasive ability to traverse reconstituted basement membranes (Matrigel) and stronger activation of proMMP-2 than other leukemia cell line such as NB4, K562, U937 and THP-1 cells.
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138666.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 9007-34-5 / Collagen; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


52. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF: Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood; 2007 Dec 15;110(13):4614-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
  • We have therefore examined whether imatinib mesylate can delay relapse and postpone the requirement for DLI in 22 patients with chronic myeloid leukemia (CML) allografted using a reduced-intensity regimen.
  • Adjunctive targeted therapy allows the kinetics of disease relapse after a reduced-intensity allograft to be manipulated and represents a novel strategy by which outcome may be improved in patients who undergo transplantation for CML and other leukemias.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Secondary Prevention


53. Tanaka J, Asaka M, Imamura M: Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia. Int J Hematol; 2005 Jan;81(1):6-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.
  • Several methods can be used to expand NKR-expressing cells for adoptive immunotherapy for leukemia and other malignant diseases.
  • We review recent developments in the biology and clinical application of NKR-expressing cells, such as NK cells, lymphokine-activated killer cells, cytokine-induced killer cells, NKT cells, and other NKR-expressing cells.
  • [MeSH-major] Immunotherapy, Adoptive / methods. Killer Cells, Natural / immunology. Leukemia / immunology. Leukemia / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2002 May 15;168(10):4864-70 [11994435.001]
  • [Cites] Eur J Immunol. 2003 Jul;33(7):2033-43 [12884870.001]
  • [Cites] Transplantation. 2004 Jul 15;78(1):1-6 [15257030.001]
  • [Cites] Int J Hematol. 2003 Oct;78(3):188-94 [14604276.001]
  • [Cites] Br J Haematol. 2003 Jul;122(2):231-9 [12846891.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):813-8 [9480992.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1177-85 [9780337.001]
  • [Cites] Cancer Immunol Immunother. 2003 Sep;52(9):525-34 [14627124.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):655-63 [9531330.001]
  • [Cites] Adv Immunol. 2000;74:181-273 [10605607.001]
  • [Cites] Cancer Immunol Immunother. 1998 Aug;46(6):318-26 [9756416.001]
  • [Cites] Eur J Immunol. 2003 Dec;33(12):3439-47 [14635054.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3442-50 [14500639.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] Immunity. 1999 Mar;10(3):281-7 [10204484.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2812-9 [12231521.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Nature. 2000 Jan 20;403(6767):325-8 [10659853.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Acta Haematol. 2001;105(2):89-91 [11408710.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):255-60 [11224526.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):795-9 [9486650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):768-74 [15073036.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Immunity. 1999 May;10(5):585-94 [10367904.001]
  • [Cites] Hum Immunol. 2002 Mar;63(3):200-10 [11872238.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4 [8265660.001]
  • [Cites] Adv Immunol. 2000;76:1-60 [11079097.001]
  • [Cites] Science. 1999 Jul 30;285(5428):730-2 [10426994.001]
  • [Cites] Adv Exp Med Biol. 1998;452:13-8 [9889954.001]
  • [Cites] Blood. 2001 May 15;97(10):3132-7 [11342440.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):287-90 [10967567.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3318-27 [9787169.001]
  • [Cites] Blood. 2004 Jul 1;104(1):170-7 [15016654.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):1-6 [12894844.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):778-83 [10792283.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):42-9 [9210707.001]
  • [Cites] Immunol Rev. 2001 Jun;181:185-92 [11513139.001]
  • [Cites] Adv Cancer Res. 1995;67:155-95 [8571814.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):1076-86 [11298332.001]
  • [Cites] J Clin Immunol. 2002 May;22(3):131-6 [12078854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11328-33 [12167676.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3122-30 [15070694.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):7-17 [12894845.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2024-32 [12406908.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1626-9 [9374463.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):879-92 [15338206.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8088-92 [9223319.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):165-71 [11557981.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1818-23 [9057668.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12433-8 [8901599.001]
  • [Cites] J Immunother. 2001 Jul-Aug;24(4):363-73 [11565838.001]
  • [Cites] Immunol Rev. 1998 Jun;163:197-215 [9700512.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3129-38 [11544298.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):751-4 [12028053.001]
  • [Cites] J Immunol. 1992 Nov 1;149(9):2945-53 [1401923.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1389-96 [12714493.001]
  • [Cites] Science. 1995 Apr 21;268(5209):403-5 [7716542.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1136-51 [15020616.001]
  • [Cites] Immunity. 2001 Feb;14(2):123-33 [11239445.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Blood. 1996 May 1;87(9):3993-4000 [8611732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10896-901 [12960383.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1172-7 [9448304.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):645-50 [8627176.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2396-402 [10498612.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):889-97 [3493432.001]
  • [Cites] Immunity. 2004 Sep;21(3):357-66 [15357947.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Immunol Rev. 1997 Feb;155:105-17 [9059886.001]
  • [Cites] Bone Marrow Transplant. 2004 Oct;34(7):595-602 [15300228.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1052-6 [11533710.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1285-95 [7908323.001]
  • [Cites] Hematol J. 2000;1(2):136-44 [11920181.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1637-44 [11104805.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3065-72 [15070686.001]
  • [Cites] Br J Haematol. 2002 Jul;118(1):136-9 [12100138.001]
  • [Cites] Haematologica. 1992 Mar-Apr;77(2):127-9 [1398297.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):11-24 [11472339.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1057-62 [11533711.001]
  • [Cites] Immunol Today. 1998 Apr;19(4):153-7 [9577090.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):821-7 [12060116.001]
  • [Cites] Blood. 2001 May 15;97(10):2923-31 [11342413.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5239-45 [9605119.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] Blood. 2003 May 1;101(9):3730-40 [12511415.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):824-32 [8625186.001]
  • (PMID = 15717681.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 93
  •  go-up   go-down


54. Levin MJ: Varicella vaccination of immunocompromised children. J Infect Dis; 2008 Mar 1;197 Suppl 2:S200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The obstacles, potential opportunities, and success in varicella vaccination for immunocompromised children are separately analyzed for (1) children with leukemia and other malignancies, (2) human immunodeficiency virus-infected children, and (3) children with hematopoietic stem cell or solid-organ transplantation.

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419398.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / PHS HHS / / H12HA00070; United States / NICHD NIH HHS / HD / N01-HD-3-3345; United States / NIAID NIH HHS / AI / U01 AI068632
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chickenpox Vaccine
  • [Number-of-references] 48
  •  go-up   go-down


55. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM: FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells; 2006 May;24(5):1174-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
  • FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias.
  • [MeSH-major] Hematopoiesis. Leukemia, Myelomonocytic, Acute / enzymology. Leukemia, Myelomonocytic, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410383.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108545; United States / NHLBI NIH HHS / HL / HL75826; United States / PHS HHS / / RHL083077A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 145
  •  go-up   go-down


56. Dunphy CH: Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med; 2006 Apr;130(4):483-520
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications.
  • OBJECTIVES: To review the literature regarding GE data that may provide important information regarding pathogenesis and that may be extrapolated for use in diagnosing and prognosticating lymphomas and leukemias; to present GE findings in Hodgkin and non-Hodgkin lymphomas, acute leukemias, and chronic myeloid leukemia in detail; and to summarize the practical clinical applications in tables that are referenced throughout the text.
  • CONCLUSIONS: Gene expression profiling of lymphomas and leukemias aids in the diagnosis and prognostication of these diseases.
  • Flow cytometric and immunohistochemical applications of the information gained from GE profiling assist in the management of chronic lymphocytic leukemia, other low-grade B-cell non-Hodgkin lymphomas and leukemias, diffuse large B-cell lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and classic Hodgkin lymphoma.
  • For practical clinical use, GE profiling of precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, and acute myeloid leukemia has supported most of the information that has been obtained by cytogenetic and molecular studies (except for the identification of FLT3 mutations for molecular analysis), but extrapolation of the analyses leaves much to be gained based on the GE profiling data.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / genetics. Lymphoma / diagnosis. Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594743.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 173
  •  go-up   go-down


57. Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin KM, Stahnke K: Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene; 2005 Mar 31;24(14):2421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia.
  • Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.
  • [MeSH-major] Antigens, CD / physiology. Antigens, CD34 / immunology. Apoptosis / physiology. Caspases / metabolism. Hematopoietic Stem Cells / cytology. Lectins, C-Type / physiology. Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735742.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Lectins, C-Type; 0 / NK Cell Lectin-Like Receptor Subfamily D; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


58. Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM, Cotelingam JD, Nordberg ML: Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther; 2007;11(4):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
  • BACKGROUND: For Philadelphia chromosome positive (Ph+) leukemias (chronic myelogenous leukemia [CML], acute lymphoblastic leukemia [ALL], and rare other leukemias), both allogeneic transplantation and treatment with tyrosine kinase inhibitors offer chances of molecular remission (the molecular marker being consistently undetectable).
  • QRT-PCR, due to its superior sensitivity, is considered the gold standard for the follow-up of Ph+ leukemias treated with imatinib.
  • AIM: The objective of our study was to compare the diagnostic and clinical usefulness of FISH and QRT-PCR at different timepoints for Ph+ leukemias.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. In Situ Hybridization, Fluorescence / methods. Leukemia / diagnosis. Leukemia / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):397-402 [16396761.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):483-91 [16945414.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):29-41 [16426942.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):33-9 [15604889.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3 Suppl 8):22-7 [11526598.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):295-9 [15354415.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):495-502 [16403813.001]
  • [Cites] Br J Haematol. 1998 Jun;101(3):552-7 [9633901.001]
  • [Cites] Leukemia. 2002 Jan;16(1):53-9 [11840263.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3425-32 [15867244.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):243-50 [15347310.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:211-8 [17124063.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):284-9 [12799534.001]
  • [Cites] Eur J Haematol. 2002 May;68(5):272-80 [12144533.001]
  • [Cites] Blood. 2000 Jan 15;95(2):404-8 [10627442.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4701-7 [12576334.001]
  • (PMID = 17705578.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


59. Cunningham SC, Fakhry K, Bass BL, Napolitano LM: Neutropenic enterocolitis in adults: case series and review of the literature. Dig Dis Sci; 2005 Feb;50(2):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we discuss two cases of neutropenic enterocolitis secondary to the administration of systemic chemotherapy in adult cancer patients: one with lung carcinoma, the other with leukemia.
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Humans. Intestine, Small / pathology. Leukemia, Erythroblastic, Acute / drug therapy. Lung Neoplasms / drug therapy. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N C Med J. 2002 May-Jun;63(3):132-4 [12181847.001]
  • [Cites] Arch Intern Med. 1973 Apr;131(4):538-44 [4512530.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):656-60 [9264347.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1797-800 [8095437.001]
  • [Cites] Am Surg. 1973 Mar;39(3):129-33 [4694020.001]
  • [Cites] Am J Clin Pathol. 1988 Mar;89(3):407-9 [3162345.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):733-6 [12591685.001]
  • [Cites] Arch Surg. 1998 Sep;133(9):979-82 [9749851.001]
  • [Cites] AJR Am J Roentgenol. 1977 Aug;129(2):347-8 [409180.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):409-14 [9690531.001]
  • [Cites] Int J Hematol. 1997 Jul;66(1):47-55 [9220660.001]
  • [Cites] Cancer. 1979 Feb;43(2):730-4 [283881.001]
  • [Cites] J Med. 1997;28(1-2):1-19 [9249606.001]
  • [Cites] Ann Intern Med. 1964 Dec;61:1084-103 [14233829.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):463-5 [12801351.001]
  • [Cites] Acta Paediatr Suppl. 1994;396:33-6 [8086679.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):209-12 [9024519.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 Nov;16(4):348-51 [7978054.001]
  • [Cites] Clin Infect Dis. 1998 Oct;27(4):695-9 [9798018.001]
  • [Cites] Arch Surg. 1973 Jul;107(1):39-42 [4714435.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):17-23 [1727660.001]
  • [Cites] Curr Gastroenterol Rep. 2002 Aug;4(4):297-301 [12149175.001]
  • [Cites] Dis Colon Rectum. 1986 Mar;29(3):196-9 [3943436.001]
  • [Cites] JAMA. 1962 Oct 6;182:23-9 [13861046.001]
  • [Cites] Am J Surg. 1986 May;151(5):563-6 [3458380.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Mar;47(3):277-9 [11320673.001]
  • [Cites] Ann Oncol. 1997 Apr;8(4):405 [9209673.001]
  • [Cites] Am J Hematol. 2001 Mar;66(3):213-9 [11279629.001]
  • [Cites] Surgery. 1993 Jan;113(1):113-6 [8417477.001]
  • [Cites] Am J Surg. 1985 Mar;149(3):405-8 [3856402.001]
  • [Cites] Am J Clin Oncol. 2000 Jun;23(3):309-13 [10857900.001]
  • [Cites] Isr J Med Sci. 1995 Feb-Mar;31(2-3):194-6 [7744595.001]
  • [Cites] Cancer. 1979 Feb;43(2):695-7 [283878.001]
  • [Cites] Pathology. 1976 Jul;8(3):247-58 [1004950.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):821-4 [2670057.001]
  • (PMID = 15745075.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


60. Nakahashi H, Tsukamoto N, Hashimoto Y, Koiso H, Yokohama A, Saitoh T, Uchiumi H, Handa H, Murakami H, Nojima Y, Karasawa M: Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders. Cancer Sci; 2009 Apr;100(4):671-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders.
  • The incidence of chronic lymphocytic leukemia is low in the Japanese population compared with populations in western countries, suggesting a role for genetic factors in the occurrence of this disease.
  • We have previously shown that chronic lymphocytic leukemia in Japan rarely expresses the immunoglobulin heavy chain variable region (IGHV) 1-69 gene (1 out of 43 patients, 2.3%), which is a gene most commonly expressed in chronic lymphocytic leukemia cases from western countries.
  • In the current study, we extended the previous study by examining immunoglobulin heavy chain and light chain gene expression in 80 Japanese patients with chronic lymphocytic leukemia and in 52 Japanese patients with other leukemic chronic lymphoproliferative disorders.
  • IGHV1-69 gene expression was again quite low in our cohort, found in only two patients: one with chronic lymphocytic leukemia and the other with splenic marginal zone lymphoma.
  • The IGHV4-34 gene was most frequently expressed in chronic lymphocytic leukemia (27.5%), whereas it was rarely found in leukemic chronic lymphoproliferative disorders (7.7%, P = 0.005).
  • There was also a significant difference in the expression of IGLV3-21 between chronic lymphocytic leukemia and leukemic chronic lymphoproliferative disorders (29.4 vs 4.8%, P = 0.018).
  • The IGLV3-21 gene in the majority of chronic lymphocytic leukemia cases was associated with homologous complementarity determining region 3 sequences.
  • We found that two patients with chronic lymphocytic leukemia and the patient with splenic marginal zone lymphoma expressed IGHV4-39/IGKV1-39 and IGHV1-69/IGKV3-20, respectively, which belong to these subsets.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Light Chains / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoproliferative Disorders / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220298.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Variable Region; 0 / Receptors, IgE; 136601-57-5 / Cyclin D1
  •  go-up   go-down


61. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH: Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet; 2005 Jun;37(6):613-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7).
  • Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.
  • [MeSH-minor] Adult. Age Factors. Animals. Cell Differentiation. Cells, Cultured. Down Syndrome / genetics. Embryo, Mammalian. Erythroid-Specific DNA-Binding Factors. GATA1 Transcription Factor. Gene Targeting. Hematopoiesis / genetics. Humans. Infant. Leukemia, Megakaryoblastic, Acute / genetics. Liver / cytology. Liver / embryology. Megakaryocytes. Mice. Transfection


62. Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K, Ito E, Ohno H, Stanley ER, Singh H, Tenen DG, Kitabayashi I: PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med; 2010 May;16(5):580-5, 1p following 585
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.
  • Leukemias and other cancers possess self-renewing stem cells that help to maintain the cancer.
  • Using an acute myeloid leukemia (AML) model induced by the leukemia-associated monocytic leukemia zinc finger (MOZ)-TIF2 fusion protein, we show here that AML can be cured by the ablation of leukemia stem cells.
  • Cells expressing high amounts of CSF1R (CSF1R(high) cells), but not those expressing low amounts of CSF1R (CSF1R(low) cells), showed potent leukemia-initiating activity.
  • Moreover, induction of AML was suppressed in CSF1R-deficient mice and CSF1R inhibitors slowed the progression of MOZ-TIF2-induced leukemia.
  • Thus, in this subtype of AML, leukemia stem cells are contained within the CSF1R(high) cell population, and we suggest that targeting of PU.1-mediated upregulation of CSF1R expression might be a useful therapeutic approach.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2002 Nov;17(5):665-76 [12433372.001]
  • [Cites] Blood. 2007 Jul 1;110(1):323-33 [17360941.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):259-71 [12676584.001]
  • [Cites] J Leukoc Biol. 2004 Apr;75(4):612-23 [14726498.001]
  • [Cites] Cancer Res. 1987 Feb 1;47(3):874-80 [2433029.001]
  • [Cites] Nature. 1987 Sep 17-23;329(6136):259-61 [3476856.001]
  • [Cites] Cell. 1987 Nov 20;51(4):663-73 [2824063.001]
  • [Cites] J Clin Invest. 1988 Apr;81(4):1030-5 [2832442.001]
  • [Cites] J Cell Physiol. 1988 Apr;135(1):133-8 [3259234.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):373-81 [8264604.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1231-40 [8622667.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):33-41 [8782817.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3127-32 [15637141.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1590-600 [15914556.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):851-3 [15917650.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):147-51 [16170366.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1175-86 [16651658.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10677-85 [18006809.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1523-7 [18754862.001]
  • [Cites] Haematologica. 2008 Oct;93(10):1591-3 [18698081.001]
  • [Cites] Blood. 2009 Jul 9;114(2):299-309 [19339695.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7184-96 [11742995.001]
  • [Cites] Blood. 2002 Jan 1;99(1):111-20 [11756160.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1321-30 [16702405.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2634-43 [17121910.001]
  • [Cites] Blood. 2007 May 1;109(9):3998-4005 [17227832.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e12 [12582257.001]
  • (PMID = 20418886.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA041456-24; United States / NCI NIH HHS / CA / R01 CA032551; United States / NCI NIH HHS / CA / P01 CA066996; United States / NCI NIH HHS / CA / 5P30-CA13330; United States / NCI NIH HHS / CA / CA041456-24; United States / NCI NIH HHS / CA / R01-CA41456; United States / NCI NIH HHS / CA / CA32551; United States / NCI NIH HHS / CA / R01 CA041456; United States / NCI NIH HHS / CA / P30 CA013330; United States / NHLBI NIH HHS / HL / R01 HL112719
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors; 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Proto-Oncogene Proteins; 0 / Receptors, Colony-Stimulating Factor; 0 / Recombinant Fusion Proteins; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS265702; NLM/ PMC3039870
  •  go-up   go-down


63. Skierski JS, Koronkiewicz M, Grieb P: Tezacitabine blocks tumor cells in G1 and S phases of the cell cycle and induces apoptotic cell death. Acta Pol Pharm; 2005 May-Jun;62(3):195-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a previous paper (3) we worked on human and murine leukemia (L-1210, HL-60, and MOLT-4) cells, and in this paper we investigated the influence of FMdC on the cell cycle and apoptosis in vitro of three other leukemias (CCRF-SB, KG-1, and Jurkat), and human solid tumor (carcinoma) cell lines (COLO-205, MCF-7, and PC-3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193812.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; UCC4EQS7WL / tezacitabine
  •  go-up   go-down


64. Yan Z, Hua H, Gao Y: Paraneoplastic pemphigus characterized by polymorphic oral mucosal manifestations--report of two cases. Quintessence Int; 2010 Sep;41(8):689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two Chinese patients, one with chronic lymphocytic leukemia and the other with thymoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lichen Planus, Oral / etiology. Oral Ulcer / etiology. Paraneoplastic Syndromes / etiology. Pemphigus / etiology. Thymoma / complications. Thymus Neoplasms / complications

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657859.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


65. zur Hausen H: Childhood leukemias and other hematopoietic malignancies: interdependence between an infectious event and chromosomal modifications. Int J Cancer; 2009 Oct 15;125(8):1764-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemias and other hematopoietic malignancies: interdependence between an infectious event and chromosomal modifications.
  • A large number of epidemiological observations suggest an infectious origin of hematopoietic malignancies, including various forms of leukemia, nonHodgkin's lymphomas, Hodgkin's lymphomas and multiple myelomas.
  • Incidence of nonHodgkin's lymphomas and Hodgkin's lymphomas, although not of leukemias, is substantially increased under immunosuppression.
  • Presently less than 10% of the global incidence of leukemias and lymphomas can be linked to infections (Epstein-Barr virus, human T-lymphotropic retrovirus, human herpesvirus type 8 and Helicobacter pylori).
  • In childhood leukemias, a protective effect was noted for multiple infections during the first year of life and for at least 6 months of breastfeeding.
  • [MeSH-major] Chromosome Aberrations. Genome, Viral / physiology. Leukemia / etiology. Lymphoma / etiology. Polyomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330827.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


66. Maghazachi AA: Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol; 2010;341:37-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, alloreactive NK cells have been successfully used to treat patients with acute myeloid leukemia and other hematological malignancies.
  • On the other hand, both NK cell subsets migrate into inflammatory sites, with more CD56(dim)CD16(bright) NK cells distributing into inflamed liver and lungs.
  • On the other hand, CD56(dim)CD16(bright) NK cells accumulate in the liver of patients with primary biliary disease aided by the CXCR1/CXCL8 axis.
  • Depending on the tissue and the chemokine secreted, NK cells may ameliorate the disease such as their roles in combating tumors or virally infected cells, and their therapeutic potentials in treating leukemias and other hematological malignancies, as well as reducing the incidence of GvH disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20369317.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Chemokines; 0 / Receptors, Chemokine
  •  go-up   go-down


67. Thompson JA, Carozza SE, Zhu L: Geographic risk modeling of childhood cancer relative to county-level crops, hazardous air pollutants and population density characteristics in Texas. Environ Health; 2008;7:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There was supportive evidence for elevated risks for germ cell tumors and "other" gliomas in areas of intense cropping and for hepatic tumors in areas of intense release of hazardous air pollutants.
  • Elevated spatial risks included four cancer histotypes, "other" leukemias, Central Nervous System (CNS) embryonal tumors, CNS other gliomas and hepatic tumors with greater than 95% likelihood of elevated risks in at least one county.
  • The current study identified geographic factors supporting more focused studies of germ cell tumors and "other" gliomas in areas of intense cropping, hepatic cancer near Hazardous Air Pollutant (HAP) release facilities and specific locations with increased risks for CNS embryonal tumors and for "other" leukemias.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):391-7 [10869308.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):626-30 [15064172.001]
  • [Cites] Environ Res. 2004 May;95(1):106-15 [15068936.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(9):1016-25 [15198922.001]
  • [Cites] Environ Health Perspect. 2004 Jul;112(10):1133-6 [15238289.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Stat Med. 1993 Oct;12(19-20):1915-29 [8272670.001]
  • [Cites] J Epidemiol Community Health. 1996 Jun;50(3):313-9 [8935464.001]
  • [Cites] Environ Health Perspect. 1997 Nov;105(11):1222-7 [9370519.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1440-8 [9762947.001]
  • [Cites] Environ Health Perspect. 1999 Mar;107(3):205-11 [10064550.001]
  • [Cites] J Epidemiol Community Health. 1998 Nov;52(11):716-26 [10396504.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):93-100 [15613951.001]
  • [Cites] Stat Methods Med Res. 2005 Feb;14(1):35-59 [15690999.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Scand J Work Environ Health. 2005;31 Suppl 1:46-54; discussion 5-7 [16190149.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2920-9 [16425269.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):102-6 [16755299.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):105-13 [17186426.001]
  • [Cites] Pediatr Clin North Am. 2007 Feb;54(1):177-203, x [17306690.001]
  • [Cites] Int J Health Geogr. 2007;6:13 [17389045.001]
  • [Cites] Pediatr Blood Cancer. 2007 Nov;49(6):797-802 [17366525.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):825-40 [17908622.001]
  • [Cites] Int J Hyg Environ Health. 2007 Oct;210(5):645-57 [17434797.001]
  • [Cites] Environ Health Perspect. 2000 Sep;108(9):873-81 [11017893.001]
  • (PMID = 18817548.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA106080; United States / NCI NIH HHS / CA / R03 CA119696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Hazardous Substances
  • [Other-IDs] NLM/ PMC2572154
  •  go-up   go-down


68. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ: Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev; 2005;37(4):611-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CPA is widely used as an anticancer drug, an immunosuppressant, and for the mobilization of hematopoetic progenitor cells from the bone marrow into peripheral blood prior to bone marrow transplantation for aplastic anemia, leukemia, and other malignancies.
  • They are activated through other enzymatic and/or non-enzymatic pathways.
  • For example, both NSC 612567 and NSC 613060 can be activated by plain phosphodiesterase (PDEs) in plasma and other tissues or by the high-affinity nuclear 3'-5' exonucleases associated with DNA polymerases, such as DNA polymerases and epsilon.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393888.001).
  • [ISSN] 0360-2532
  • [Journal-full-title] Drug metabolism reviews
  • [ISO-abbreviation] Drug Metab. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Phosphoramide Mustards
  • [Number-of-references] 639
  •  go-up   go-down


69. Wu Y, Sommers JA, Suhasini AN, Leonard T, Deakyne JS, Mazin AV, Shin-Ya K, Kitao H, Brosh RM Jr: Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes. Blood; 2010 Nov 11;116(19):3780-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fanconi anemia (FA) is a genetic disease characterized by congenital abnormalities, bone marrow failure, and susceptibility to leukemia and other cancers.

  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 17;19(14):3799-810 [10899133.001]
  • [Cites] Annu Rev Genet. 2009;43:223-49 [19686080.001]
  • [Cites] Nature. 2003 May 15;423(6937):305-9 [12748644.001]
  • [Cites] Nature. 2003 May 15;423(6937):309-12 [12748645.001]
  • [Cites] Hum Mutat. 2003 Aug;22(2):121-8 [12872252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2357-62 [14983014.001]
  • [Cites] BMC Cancer. 2004 Mar 12;4:9 [15113441.001]
  • [Cites] J Mol Biol. 2004 Dec 10;344(5):1265-86 [15561143.001]
  • [Cites] J Mol Biol. 2004 Dec 10;344(5):1287-309 [15561144.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25450-60 [15878853.001]
  • [Cites] Nat Genet. 2005 Sep;37(9):934-5 [16116423.001]
  • [Cites] Nat Genet. 2005 Sep;37(9):931-3 [16116424.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):255-65 [16153896.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1005-16 [16280053.001]
  • [Cites] BMC Cancer. 2006;6:19 [16430786.001]
  • [Cites] Mol Cell. 2006 Sep 15;23(6):801-8 [16973432.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1239-41 [17033622.001]
  • [Cites] BMC Cancer. 2007;7:83 [17504528.001]
  • [Cites] EMBO J. 2007 Jul 11;26(13):3238-49 [17581638.001]
  • [Cites] Nat Struct Mol Biol. 2007 Aug;14(8):746-53 [17660833.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(19):6733-41 [17664283.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2390-8 [17596542.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9591-6 [17909071.001]
  • [Cites] Genes Dev. 2007 Dec 1;21(23):3085-94 [18003860.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1732-43 [18029358.001]
  • [Cites] Cell. 2008 May 30;133(5):789-800 [18510924.001]
  • [Cites] Cell. 2008 May 30;133(5):801-12 [18510925.001]
  • [Cites] Mol Cell Biol. 2008 Jun;28(12):4116-28 [18426915.001]
  • [Cites] PLoS Biol. 2008 Jun 24;6(6):e149 [18578568.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4672-80 [18628483.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36132-9 [18978354.001]
  • [Cites] Biochemistry. 2009 Feb 10;48(5):1036-46 [19154117.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):4829-35 [19074432.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):7505-17 [19150983.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(1):51-5 [18483852.001]
  • [Cites] J Biol Chem. 2009 Jul 3;284(27):18458-70 [19419957.001]
  • [Cites] Mutat Res. 2009 Jul 31;668(1-2):20-6 [19379763.001]
  • [Cites] Mutat Res. 2009 Jul 31;668(1-2):4-10 [19622403.001]
  • [Cites] Mol Cell. 2009 Sep 11;35(5):694-703 [19748362.001]
  • [Cites] Cell. 2001 Apr 6;105(1):149-60 [11301010.001]
  • (PMID = 20639400.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100839; United States / NCI NIH HHS / CA / R56 CA100839; United States / NCI NIH HHS / CA / CA100839; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BACH1 protein, human; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Fanconi Anemia Complementation Group Proteins; 0 / Mutant Proteins; 0 / Oxazoles; 0 / Recombinant Proteins; 0 / telomestatin; 50SG953SK6 / Mitomycin; 8L70Q75FXE / Adenosine Triphosphate; 9007-49-2 / DNA; E1UOL152H7 / Iron; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.4.- / DNA Helicases
  • [Other-IDs] NLM/ PMC2981534
  •  go-up   go-down


70. Jerse M, Mlakar U, Popovic M, Vranic A, Zidar N: Granulocytic sarcoma in a patient with essential thrombocythemia presented as acute spinal cord compression--case report and review of the literature. Clin Neuropathol; 2008 Jul-Aug;27(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma (GS) is a rare solid tumor of myeloid origin, which usually precedes or occurs concurrently with myeloid leukemia, or with other types of myeloproliferative and myelodysplastic disorders.
  • We present a case of a 75-year-old woman with a long history of essential thrombocythemia who developed 2 tumors: 1 in the bodies of T3 - 6 vertebras extending epidurally, and the other in the right frontal lobe, adherent to dura, thus, mimicking meningioma.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666440.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antigens, CD; 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan; R16CO5Y76E / Aspirin
  •  go-up   go-down


71. Boice JD Jr, Mumma MT, Blot WJ: Cancer mortality among populations residing in counties near the Hanford site, 1950-2000. Health Phys; 2006 May;90(5):431-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid cancer (n=33; RR 0.84; 95% CI 0.56-1.26), female breast cancer (n=1,233; RR 0.99; 95% CI 0.92-1.06), leukemia other than chronic lymphocytic leukemia (n=492; RR 0.95; 95% CI 0.85-1.06), and childhood leukemia (n=71; RR=1.06; 95% CI 0.78-1.43) were not significantly increased in the exposed counties.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607175.001).
  • [ISSN] 0017-9078
  • [Journal-full-title] Health physics
  • [ISO-abbreviation] Health Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


72. Valmary S, Danjoux M, Delsol G, Brousset P: [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology]. Ann Pathol; 2005 Feb;25(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic lymphomas, 2 Burkitt's lymphomas, 5 B and T acute lymphoblastic leukemias and 2 acute monoblastic leukemias.
  • Significant numbers of cases of acute myeloblastic leukemias are TdT positive but could be easily distinguished from lymphoblastic proliferations.
  • CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating lymphoma/acute lymphoblastic leukemia from other lymphomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / diagnosis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukemia, Monocytic, Acute / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981929.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


73. Redel-Montero J, Bujalance-Cabrera C, Vaquero-Barrios JM, Santos-Luna F, Arenas-De Larriva M, Moreno-Casado P, Espinosa-Jiménez D: Lung transplantation for bronchiolitis obliterans after allogenic bone marrow transplantation. Transplant Proc; 2010 Oct;42(8):3023-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABMT was indicated after bone marrow aplasia in 2 cases and acute myeloid leukemia in the other patient.
  • Two of the subjects required changes in the immunosuppressive regimen: 1 due to chronic graft rejection with subsequent functional recovery and the other due to hematologic and neurologic toxicity.


74. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A: Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma; 2009 Nov;50(11):1803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Nov;50(11):1733-4 [19883301.001]
  • (PMID = 19860621.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


75. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S: Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood; 2005 Feb 15;105(4):1706-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
  • Interactions between the Chk1 inhibitor UCN-01 and the farnesyltransferase inhibitor L744832 were examined in human leukemia cells.
  • Similar interactions were noted in other leukemia cells (HL-60, Raji, Jurkat) and primary acute myeloid leukemia (AML) blasts.
  • Together, these findings suggest that farnesyltransferase inhibitors interrupt the cytoprotective Akt and MAPK pathways while reciprocally activating SAPK/JNK in leukemia cells exposed to UCN-01 and, in so doing, dramatically increase mitochondria-dependent apoptosis.
  • [MeSH-major] Alkyl and Aryl Transferases / antagonists & inhibitors. Apoptosis / drug effects. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. JNK Mitogen-Activated Protein Kinases / metabolism. Leukemia, Myeloid / drug therapy. MAP Kinase Kinase 4 / metabolism. MAP Kinase Signaling System / drug effects. Methionine / analogs & derivatives. Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins / antagonists & inhibitors. Staurosporine / analogs & derivatives. Staurosporine / metabolism


76. Altieri A, Castro F, Bermejo JL, Hemminki K: Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol Biomarkers Prev; 2006 Jul;15(7):1281-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology.
  • Epidemiologic evidence indicates that several markers of exposure to childhood infections are inversely associated with the risk of childhood leukemia and lymphomas.
  • We used the Swedish Family-Cancer Database to assess the effects of number of siblings on the risk of non-Hodgkin's (n = 7,007) and Hodgkin's lymphomas (n = 3,115), leukemias (n = 7,650), and multiple myeloma (n = 1,492) by histopathology.
  • Having four or more siblings compared with none was associated with an excess risk of childhood acute lymphoblastic leukemia [ALL; rate ratio (RR), 2.11; P(trend) = 0.001], acute monocytic leukemia (RR, 2.51; P(trend) = 0.002), and multiple myeloma (RR, 1.34; P(trend) = 0.006).
  • Having three or more older siblings compared with none decreased the risk of acute monocytic leukemia (RR, 0.35; P(trend) = 0.001) and childhood ALL (RR, 0.69; P(trend) = 0.01).
  • Acute myeloid leukemia, chronic lymphocytic leukemia, and other lymphoproliferative malignancies were not associated with number of siblings.
  • In conclusion, we found an excess risk of childhood ALL and acute monocytic leukemia in large families.
  • However, for ALL, acute monocytic leukemia, and Hodgkin's lymphoma, younger siblings were strongly protected compared with older siblings.
  • The remarkable protective effect of number of older siblings on acute monocytic leukemia is a novel finding of potential interest.
  • [MeSH-major] Birth Order. Hodgkin Disease / etiology. Leukemia / etiology. Multiple Myeloma / etiology. Siblings

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835324.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Bäsecke J, Podleschny M, Clemens R, Schnittger S, Viereck V, Trümper L, Griesinger F: Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults. Leuk Res; 2006 Sep;30(9):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Like other leukemia associated aberrations they are also present in healthy adults.
  • [MeSH-major] Gene Duplication. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540167.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


78. Awan H, Jønsson V, Johannesen TB, Ly B, Tjønnfjord GE: Anticipation in families with chronic lymphocytic leukemia and other lymphoproliferative disorders. Transl Oncogenomics; 2010 Mar 30;4:1-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticipation in families with chronic lymphocytic leukemia and other lymphoproliferative disorders.
  • Fifty-one parent-offspring pairs with chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders (nonCLL) such as malignant lymphoma, multiple myeloma, or other types of lymphocytic leukemia than CLL were ascertained independently in 38 families.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Jun;109(4):794-9 [10929032.001]
  • [Cites] Hum Genet. 2000 May;106(5):553-6 [10914686.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Br J Haematol. 2001 May;113(2):407-14 [11380406.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1008-14 [12040432.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):113-7 [12407690.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50 [15894680.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):648-9 [16098083.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):729-42 [16205713.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):743-55 [16205714.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2115-27 [17071485.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):157-66 [16616062.001]
  • [Cites] Trends Genet. 2007 Apr;23(4):192-9 [17316885.001]
  • [Cites] Science. 2007 Mar 30;315(5820):1800-1 [17395816.001]
  • [Cites] Science. 2007 Apr 20;316(5823):398-9 [17446388.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):630-4 [18021078.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Am J Hum Genet. 1996 Jul;59(1):264-8 [8659536.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):973-9 [8900222.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):270-2 [9634521.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1696-8 [9823943.001]
  • [Cites] Med Oncol. 2007;24(1):55-62 [17673812.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1987-90 [12481897.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):73-9 [17116127.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):72-9 [10651726.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):290-3 [11071392.001]
  • (PMID = 21566766.001).
  • [ISSN] 1177-2727
  • [Journal-full-title] Translational oncogenomics
  • [ISO-abbreviation] Transl Oncogenomics
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3072649
  • [Keywords] NOTNLM ; chronic lymphocytic leukemia / epigenetic inheritance / familial clustering / malignant lymphomas / multiple myeloma
  •  go-up   go-down


79. Ravandi F, O'Brien S: Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc; 2005 Dec;80(12):1660-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
  • The distinction between lymphoma and leukemia is somewhat arbitrary and is based on variable involvement of the bone marrow, peripheral blood, and lymphatic system.
  • [MeSH-major] Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342661.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


80. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, Zelent A, de Thé H, Gronemeyer H: Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res; 2005 Oct 1;65(19):8754-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.
  • Apart from PML-retinoic acid receptor-alpha (RARalpha) acute promyelocytic leukemia all other acute myeloid leukemias (AML) are unresponsive to retinoid differentiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cyclic AMP / metabolism. Cyclic AMP-Dependent Protein Kinases / metabolism. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Phosphodiesterase Inhibitors / pharmacology. Receptors, Retinoic Acid / metabolism. Retinoid X Receptors / agonists
  • [MeSH-minor] Acute Disease. Animals. Apoptosis / drug effects. Cell Differentiation / drug effects. Drug Synergism. HL-60 Cells. Humans. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / pathology. Mice. Receptor Cross-Talk. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / physiology. U937 Cells

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204045.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 0 / Receptors, Retinoic Acid; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Retinoid X Receptors; 0 / TNFRSF10B protein, human; 0 / Tnfrsf10b protein, mouse; 0 / retinoic acid receptor alpha; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


81. Bertaina A, Bernardo ME, Caniglia M, Vinti L, Giorgiani G, Locatelli F: Cord blood transplantation in children with haematological malignancies. Best Pract Res Clin Haematol; 2010 Jun;23(2):189-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since it has been demonstrated that an inverse correlation between the number of nucleated cord blood cells infused per kg recipient body weight and the risk of dying for transplantation-related causes exists, recently developed strategies aimed at increasing the number of cord blood progenitors and at favouring stem cell homing could further optimize the outcome of children with leukemia or other malignancies receiving UCBT.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20837330.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


82. Qazi HA, Manikandan R, Foster CS, Fordham MV: Testicular metastasis from gastric carcinoma. Urology; 2006 Oct;68(4):890.e7-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other than leukemias and lymphomas, the most common sites from which metastases occur are the lung and prostate gland.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070383.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Ozato K, Tailor P, Kubota T: The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem; 2007 Jul 13;282(28):20065-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IRFs also regulate growth and differentiation of many cell types, thus playing a role in leukemia and other cancers.
  • [MeSH-major] Immunity, Innate. Interferon Regulatory Factors / immunology. Interferon Type I / immunology. Leukemia / immunology. Transcription, Genetic / immunology. Virus Diseases / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502370.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Interferon Type I
  • [Number-of-references] 55
  •  go-up   go-down


84. Amiel A, Goldzak G, Gaber E, Fejgin MD: Molecular cytogenetic characteristics of Down syndrome newborns. J Hum Genet; 2006;51(6):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Down syndrome (DS) is a multifactorial disorder with a high predisposition to leukemia and other malignancies.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683054.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Elghissassi I, Inrhaoun H, Mrabti H, Errihani H: Nonleukemic granulocytic sarcoma of knee: a case report. Case Rep Med; 2010;2010:235295
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is usually associated with leukemia or other myeloproliferative disorders.
  • There was no systemic manifestation of leukemia, and bone marrow biopsiy was negative for neoplastic infiltration.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Cleve Clin J Med. 1991 Nov-Dec;58(6):471-4 [1752028.001]
  • [Cites] Pediatr Int. 2001 Oct;43(5):505-7 [11737714.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):431-4 [12768322.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2527-41 [17169797.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1370-8 [18623376.001]
  • [Cites] Acta Haematol. 2009;122(4):238-46 [19887783.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2003 Nov;24(11):568-71 [14720440.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • [Cites] Intern Med. 2007;46(9):633-5 [17473505.001]
  • [Cites] Clin Transl Oncol. 2008 Nov;10(11):758-60 [19015073.001]
  • [Cites] Int J Hematol. 2009 Jan;89(1):95-7 [19109732.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • (PMID = 21209806.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3014795
  •  go-up   go-down


86. Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brümmendorf TH: Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol; 2005 May;33(5):542-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Imatinib mesylate is a novel tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome positive (Ph+) leukemia and other malignancies.
  • In previous studies, we found significant telomere shortening in Ph+ cells from patients with chronic myeloid leukemia (CML).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850831.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Culture Media; 0 / Interleukin-3; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


87. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):381-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although based on small number of cases, the association between elevated plasma CRP level and risk was stronger for cancers of the liver, lung, skin, kidney, and bladder, as well as for lymphoma and leukemia than for other neoplasms.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492932.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


88. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S: Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem; 2010 Mar 26;285(13):10064-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.
  • Mechanisms underlying histone deacetylase inhibitor (HDACI)-mediated NF-kappaB activation were investigated in human leukemia cells.
  • Exposure of U937 and other leukemia cells to LBH-589 induced reactive oxygen species (ROS) followed by single strand (XRCC1) and double strand (gamma-H2AX) DNA breaks.
  • Together, these findings indicate that in human leukemia cells, HDACIs activate the cytoprotective NF-kappaB pathway through an ATM/NEMO/SUMOylation-dependent process involving the induction of ROS and DNA damage and suggest that blocking NF-kappaB activation via the atypical ATM/NEMO nuclear pathway can enhance HDACI antileukemic activity.
  • [MeSH-major] Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Leukemic. Histone Deacetylase Inhibitors / metabolism. Leukemia / drug therapy. Leukemia / enzymology. NF-kappa B / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2687-95 [10733571.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1653-7 [11533489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7065-77 [11564889.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3917-24 [12032830.001]
  • [Cites] J Virol. 2002 Nov;76(21):11091-103 [12368351.001]
  • [Cites] EMBO J. 2002 Dec 2;21(23):6539-48 [12456660.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):155-68 [12612651.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Genes Dev. 2003 Apr 1;17(7):873-82 [12654725.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18980-9 [12649266.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):489-90 [12776118.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3637-45 [12839953.001]
  • [Cites] EMBO J. 2003 Jul 1;22(13):3356-66 [12839997.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6200-9 [12917341.001]
  • [Cites] Cell Cycle. 2003 Sep-Oct;2(5):467-72 [12963846.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):549-57 [12920522.001]
  • [Cites] Cell. 2003 Sep 19;114(6):673-88 [14505568.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):829-39 [14580335.001]
  • [Cites] Cell. 2003 Nov 26;115(5):565-76 [14651848.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jan;3(1):17-26 [14708018.001]
  • [Cites] Novartis Found Symp. 2004;259:208-17; discussion 218-25 [15171256.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28209-19 [15087454.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] Eur Cytokine Netw. 1996 Apr-Jun;7(2):93-124 [8688493.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):211-6 [9653098.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):93-102 [9926924.001]
  • [Cites] Nat Struct Mol Biol. 2004 Nov;11(11):1037-43 [15523479.001]
  • [Cites] Biochem J. 2004 Dec 15;384(Pt 3):543-9 [15330761.001]
  • [Cites] FEBS Lett. 2004 Dec 3;578(1-2):111-5 [15581626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 [15637150.001]
  • [Cites] Cell. 2005 Mar 11;120(5):649-61 [15766528.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):605-11 [15758953.001]
  • [Cites] EMBO Rep. 2005 Apr;6(4):321-6 [15809659.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3971-93 [15897549.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5429-44 [15964800.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):758-65 [16056267.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):773-84 [16410802.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):687-92 [16485032.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21698-709 [16740634.001]
  • [Cites] Mol Cancer Res. 2006 Aug;4(8):563-73 [16877702.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):986-93 [16906147.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15540-5 [17030815.001]
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Biotechniques. 2005 Nov;39(5):715-25 [16315372.001]
  • [Cites] Gene. 2005 Dec 19;363:15-23 [16289629.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1079-92 [16360037.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1110-1 [16497923.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1141-6 [16497931.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1493-505 [16723122.001]
  • [Cites] Cell Death Differ. 2006 Dec;13(12):2033-41 [16628233.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11298-304 [17145876.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jan;6(1):21-2 [17269160.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):641-51 [16862178.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2299-307 [17043643.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5318-27 [17545612.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5499-513 [17548474.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2642-54 [17431096.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2284-92 [17890907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7 [18042714.001]
  • [Cites] Cell. 2008 Feb 8;132(3):344-62 [18267068.001]
  • [Cites] Mol Cell. 2008 Apr 11;30(1):61-72 [18406327.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Mol Immunol. 2008 Sep;45(15):3984-9 [18657320.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3285-97 [18852132.001]
  • [Cites] Nat Rev Immunol. 2008 Nov;8(11):837-48 [18927578.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):2-10 [18978338.001]
  • [Cites] Oncogene. 2009 Feb 26;28(8):1099-109 [19079347.001]
  • [Cites] Annu Rev Immunol. 2009;27:693-733 [19302050.001]
  • [Cites] J Mol Biol. 2009 Jun 12;389(3):495-510 [19409903.001]
  • [Cites] Oncogene. 2009 Jun 4;28(22):2205-18 [19398952.001]
  • [Cites] Mol Cancer Res. 2006 Feb;4(2):125-33 [16513843.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6867-74 [10602462.001]
  • [RetractionIn] J Biol Chem. 2016 Aug 19;291(34):17535 [27543593.001]
  • (PMID = 20065354.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA130805; United States / NCI NIH HHS / CA / CA63753; United States / NCI NIH HHS / CA / R01 CA100866; United States / NCI NIH HHS / CA / R01 CA063753; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA100866; United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / R01 CA141703; United States / NCI NIH HHS / CA / P30 CA016059; United States / NCI NIH HHS / CA / CA93738; United States / NIDDK NIH HHS / DK / R01 DK052825; United States / NCI NIH HHS / CA / R01 CA150214
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Histone Deacetylase Inhibitors; 0 / IKBKG protein, human; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / SUMO-1 Protein; 0 / SUMO1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / I-kappa B Kinase
  • [Other-IDs] NLM/ PMC2843169
  •  go-up   go-down


89. Grant S, Dent P: Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias. Curr Drug Targets; 2007 Jun;8(6):751-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
  • The last decade has witnessed the introduction of a large number of novel, molecularly targeted agents into the therapeutic armamentarium against diverse forms of cancer, including leukemia.
  • While most of these agents have been or are currently being evaluated in adult patients with acute leukemia, experience in childhood leukemia is very limited.
  • In in vitro studies, highly synergistic antileukemic interactions have been reported between CDK and HDAC inhibitors; HDAC and proteasome inhibitors; Bcl-2 antagonists and CDK inhibitors; MEK/ERK and Chk1 inhibitors, and proteasome and CDK inhibitors, among other combinations.
  • Some of these strategies, including combinations of HDAC and CDK inhibitors, and CDK and proteasome inhibitors, have now entered the clinical arena in patients with leukemia and other hematologic malignancies.
  • Based upon preclinical results to date, there is reason to suspect that such strategies might prove to be active against several types of childhood leukemia.
  • Thus, over the next decade, the introduction of molecularly targeted agents, alone and in combination, into the therapeutic armamentarium against childhood leukemia may have significant implications for children with this disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Cycle / drug effects. Drug Delivery Systems. Leukemia / drug therapy. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584030.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-100866; United States / NCI NIH HHS / CA / CA-63753; United States / NCI NIH HHS / CA / CA-93738; United States / NCI NIH HHS / CA / CA88906; United States / NIDDK NIH HHS / DK / DK52825
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 118
  •  go-up   go-down


90. Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M: Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar Drugs; 2008;6(3):480-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells.
  • Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge Dactylospongia elegans, was previously reported by us to induce erythroid differentiation and G1 phase arrest of K562 chronic myelogenous leukemia cells.
  • In this study, we investigated the effect of smenospongine on the cell cycles of other leukemia cells, including HL60 human acute promyelocytic leukemia cells and U937 human histiocytic lymphoma cells by flow cytometric analysis.
  • [MeSH-major] Apoptosis / drug effects. G1 Phase / drug effects. Leukemia / drug therapy. Porifera / chemistry. Quinones / chemistry. Quinones / pharmacology. Sesquiterpenes / chemistry. Sesquiterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):121-32 [16949736.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12 [17970609.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):426-31 [11401476.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1079-90 [12234611.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):363-9 [15057141.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2004 Aug;52(8):935-7 [15304984.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2325-30 [15330179.001]
  • [Cites] Blood. 1975 Mar;45(3):321-34 [163658.001]
  • [Cites] Nature. 1982 Dec 23;300(5894):765-7 [6960256.001]
  • [Cites] Leukemia. 1992 Aug;6(8):839-42 [1640738.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):710-5 [10200527.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):101-6 [16480688.001]
  • (PMID = 19005580.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinones; 0 / Sesquiterpenes; 0 / smenospongine
  • [Other-IDs] NLM/ PMC2579737
  • [Keywords] NOTNLM ; G1 arrest / Rb / Smenospongine / apoptosis / leukemia cells / p21
  •  go-up   go-down


91. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q: TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood; 2008 Sep 15;112(6):2474-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nucleophosmin (NPM) is frequently overexpressed in leukemias and other tumors.
  • Using an inflammation-associated leukemia model, we demonstrate that TAT-NPMDeltaC induced proliferative suppression and apoptosis of preleukemic stem cells and significantly delayed leukemic development in mice.
  • [MeSH-major] Apoptosis / drug effects. Gene Products, tat / therapeutic use. Leukemia / drug therapy. Nuclear Proteins / administration & dosage. Peptide Fragments / administration & dosage

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16536-45 [16608843.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53 [16287968.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1163-70 [17277230.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3283-95 [17960249.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24451-7 [10829026.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] J Neurosci. 2002 Jul 1;22(13):5423-31 [12097494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17107-12 [12475933.001]
  • [Cites] Cancer Treat Rev. 2003 May;29 Suppl 1:41-8 [12738242.001]
  • [Cites] Trends Pharmacol Sci. 2003 May;24(5):216-8 [12767717.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8432-40 [14627984.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):985-96 [14729947.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3703-11 [15082766.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28209-19 [15087454.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):107-13 [15226358.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41275-9 [15310764.001]
  • [Cites] J Biol Chem. 1988 Aug 5;263(22):10608-12 [3392030.001]
  • [Cites] Biochemistry. 1989 Feb 7;28(3):1033-9 [2713355.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3372-7 [1596895.001]
  • [Cites] J Pathol. 1996 Jan;178(1):48-52 [8778315.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1442-6 [9108443.001]
  • [Cites] Nat Med. 1997 Jun;3(6):632-8 [9176489.001]
  • [Cites] Cell. 1997 Oct 31;91(3):325-34 [9363941.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):587-96 [9482104.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3485-95 [10207072.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):298-304 [10344220.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1569-72 [10477521.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1258-71 [15684379.001]
  • [Cites] Nature. 2005 Sep 1;437(7055):147-53 [16007073.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Leuk Res. 2005 Dec;29(12):1415-23 [15964625.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • (PMID = 18574026.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL048546; United States / NCI NIH HHS / CA / R01 CA109641; United States / NHLBI NIH HHS / HL / R01 HL072321; United States / NHLBI NIH HHS / HL / R01 HL076712
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; 117896-08-9 / nucleophosmin
  • [Other-IDs] NLM/ PMC2532814
  •  go-up   go-down


92. Romano G: The role of adult stem cells in carcinogenesis. Drug News Perspect; 2005 Nov;18(9):555-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These are indeed the essential steps in tissue regeneration, which in some cases occurs constitutively, whereas in other cases happens in response to an injury.
  • In addition, rare subpopulations of cancer stem cells were identified for leukemia and other solid tumors.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Prous Science
  • (PMID = 16421628.001).
  • [ISSN] 0214-0934
  • [Journal-full-title] Drug news & perspectives
  • [ISO-abbreviation] Drug News Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / BMI1 protein, human; 0 / DNA-Binding Proteins; 0 / Glycoproteins; 0 / MECOM protein, human; 0 / Nuclear Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Peptides; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; EC 6.3.2.19 / Polycomb Repressive Complex 1
  • [Number-of-references] 46
  •  go-up   go-down


93. Miyajima N, Watanabe M, Ohashi E, Mochizuki M, Nishimura R, Ogawa H, Sugano S, Sasaki N: Relationship between retinoic acid receptor alpha gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells. J Vet Intern Med; 2006 Mar-Apr;20(2):348-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoids show antitumor effects on human acute promyelocytic leukemia and other tumors via retinoid receptors.
  • However, remarkable antiproliferative effects of ATRA treatments were not observed on other tumor cell lines with moderate or low RARalpha mRNA expression.

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594593.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


94. Heemskerk MH: T-cell receptor gene transfer for the treatment of leukemia and other tumors. Haematologica; 2010 Jan;95(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor gene transfer for the treatment of leukemia and other tumors.
  • [MeSH-major] Gene Transfer Techniques / trends. Leukemia / genetics. Leukemia / therapy. Receptors, Antigen, T-Cell / administration & dosage. Receptors, Antigen, T-Cell / genetics. T-Lymphocyte Subsets / transplantation

  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2008 Jan 1;180(1):391-401 [18097040.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2331-8 [17082316.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7736-46 [18490778.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2278-86 [18566328.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):164-70 [19109147.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2034-41 [19223543.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):209-14 [19321326.001]
  • [Cites] Blood. 2009 Jul 16;114(3):535-46 [19451549.001]
  • [Cites] Haematologica. 2009 Sep;94(9):1316-20 [19734426.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2888-99 [19589923.001]
  • [Cites] Haematologica. 2010 Jan;95(1):126-34 [19679884.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] Gene Ther. 2000 Aug;7(16):1369-77 [10981663.001]
  • [Cites] Nat Immunol. 2001 Oct;2(10):957-61 [11577349.001]
  • [Cites] Nat Med. 2003 Apr;9(4):367-9 [12669036.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3530-40 [12869497.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):885-94 [15051765.001]
  • [Cites] Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):131-6 [9435856.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3062-7 [16020516.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3331-7 [16540688.001]
  • [Cites] Clin Immunol. 2006 May;119(2):135-45 [16458072.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8878-86 [16951205.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Blood. 2007 Jan 1;109(1):235-43 [16968899.001]
  • [CommentOn] Haematologica. 2010 Jan;95(1):126-34 [19679884.001]
  • (PMID = 20065080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2805754
  •  go-up   go-down


95. Gleissner B, Goekbuget N, Rieder H, Arnold R, Schwartz S, Diedrich H, Schoch C, Heinze B, Fonatsch C, Bartram CR, Hoelzer D, Thiel E, GMALL Study Group: CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood; 2005 Dec 15;106(13):4054-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).
  • Immunophenotyping disclosed CD10 negativity in 70 of 2408 cases of B-lineage acute lymphoblastic leukemia (ALL), although other criteria followed classification of pre-B ALL (eg, cytoplasmic immunoglobulin positivity).
  • [MeSH-major] Chromosome Aberrations. Neprilysin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123216.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


96. Krestinina L, Preston DL, Davis FG, Epifanova S, Ostroumova E, Ron E, Akleyev A: Leukemia incidence among people exposed to chronic radiation from the contaminated Techa River, 1953-2005. Radiat Environ Biophys; 2010 May;49(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia incidence among people exposed to chronic radiation from the contaminated Techa River, 1953-2005.
  • Between 1953 and 2005, 93 first primary cases of leukemia, including 23 cases of chronic lymphatic leukemia (CLL), were ascertained among the cohort members.
  • A significant linear dose-response relationship was seen for leukemias other than CLL (P < 0.001), but not for CLL.
  • The estimated excess relative risk per Gy is 4.9 (95% confidence interval (CI): 1.6; 14.3) for leukemias other than CLL and less than 0 (95% upper bound 1.4) for CLL.
  • [MeSH-major] Environmental Exposure / adverse effects. Leukemia / epidemiology. Leukemia / etiology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / etiology. Rivers

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1994 Sep 7;86(17):1315-24 [8064889.001]
  • [Cites] Radiat Res. 2008 Dec;170(6):711-20 [19138038.001]
  • [Cites] Radiat Res. 2004 Oct;162(4):377-89 [15447045.001]
  • [Cites] Sci Total Environ. 1994 Mar 1;142(1-2):1-8 [8178126.001]
  • [Cites] Health Phys. 2000 Jul;79(1):24-35 [10855775.001]
  • [Cites] Radiat Res. 2003 Jun;159(6):787-98 [12751962.001]
  • [Cites] Radiat Res. 2008 Dec;170(6):721-35 [19138033.001]
  • [Cites] J Radiol Prot. 2006 Mar;26(1):17-32 [16522942.001]
  • [Cites] Int J Epidemiol. 2007 Oct;36(5):1038-46 [17768163.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):602-11 [16238437.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):591-601 [16238436.001]
  • [Cites] Health Phys. 2000 May;78(5):542-54 [10772028.001]
  • [Cites] Radiat Res. 1997 Jul;148(1):54-63 [9216619.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • (PMID = 20012750.001).
  • [ISSN] 1432-2099
  • [Journal-full-title] Radiation and environmental biophysics
  • [ISO-abbreviation] Radiat Environ Biophys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


97. McCarthy BA, Boyle E, Wang XP, Guzowski D, Paul S, Catera R, Trott J, Yan XJ, Croce CM, Damle R, Yancopoulos S, Messmer BT, Lesser M, Allen SL, Rai KR, Chiorazzi N: Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med; 2008 Sep-Oct;14(9-10):618-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).
  • Here we show that Bcl-2 also can position on the outer cell surface membrane of B cells from patients with chronic lymphocytic leukemia (B-CLL) and certain other leukemias that do not classically possess the chromosomal breakpoint t(14;18).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Apr;13(4):501-2 [12056698.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3322-30 [18362212.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):28-37 [12510191.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):952-6 [12931191.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;148:105-50 [12698322.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Science. 1985 Sep 27;229(4720):1390-3 [3929382.001]
  • [Cites] Mol Cell Biol. 1989 Feb;9(2):701-10 [2651903.001]
  • [Cites] Adv Immunol. 1989;47:117-85 [2479233.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:663-98 [1809356.001]
  • [Cites] Int Immunol. 1992 Feb;4(2):243-52 [1377947.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4701-14 [8402648.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] J Biol Chem. 1993 Dec 5;268(34):25265-8 [8244956.001]
  • [Cites] Clin Immunol Immunopathol. 1994 Apr;71(1):14-8 [8137555.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16521-4 [8206964.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3440-6 [7949099.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1445-9 [7878463.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):612-8 [8826882.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] J Neurochem. 1998 Jan;70(1):31-9 [9422344.001]
  • [Cites] Annu Rev Immunol. 1998;16:395-419 [9597135.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Cell Sci. 1998 Oct;111 ( Pt 19):2911-22 [9730983.001]
  • [Cites] Leuk Res. 1999 Feb;23(2):127-36 [10071128.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Cell. 2005 Aug 26;122(4):593-603 [16122426.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1351-9 [16763616.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40493-502 [17090549.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52 [17717517.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4479-84 [17765227.001]
  • [Cites] Neoplasia. 2007 Oct;9(10):871-81 [17971907.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7254-63 [18094405.001]
  • [Cites] Cell Prolif. 2002 Aug;35(4):193-206 [12153612.001]
  • (PMID = 18633450.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA087956; United States / NCI NIH HHS / CA / R01 CA87956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2464573
  •  go-up   go-down


98. Novaretti MC, Domingues AE, Manhani R, Pinto EM, Dorlhiac-Llacer PE, Chamone DA: ABO genotyping in leukemia patients reveals new ABO variant alleles. Genet Mol Res; 2008;7(1):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO genotyping in leukemia patients reveals new ABO variant alleles.
  • The aim of the present study was to perform ABO genotyping in patients with leukemia.
  • Blood samples were collected from 108 Brazilian patients with chronic myeloid leukemia (N = 69), chronic lymphoid leukemia (N = 13), acute myeloid leukemia (N = 15), and acute lymphoid leukemia (N = 11).
  • We identified 22 new ABO*variants in the coding region of the ABO gene in 25 individuals with leukemia (23.2%).
  • Elucidation of the diversity of this gene in leukemia and in other diseases is important for the determination of the effect of changes in an amino acid residue on the specificity and activity of ABO glycosyltransferases and their function.
  • In conclusion, this is the first report of a large number of patients with leukemia genotyped for ABO.
  • The findings of this study indicate that there is a high level of recombinant activity in the ABO gene in leukemia patients, revealing new ABO variants.
  • [MeSH-major] ABO Blood-Group System / genetics. Alleles. Genetic Variation. Leukemia / blood

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273824.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 9007-49-2 / DNA
  •  go-up   go-down


99. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol; 2007 Oct;12(5):327-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
  • Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality.
  • Clinical studies of the other compounds, including SKI-606 and INNO-406, have been performed in rapid succession.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use


100. Imagawa E, Matsuda K, Hidaka E, Uhara M, Uehara T, Sano K, Yamauchi K: [A case of myeloid sarcoma diagnosed by FISH]. Rinsho Byori; 2007 Dec;55(12):1084-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor mass may precede or occur concurrently with acute or chronic myeloid leukemia or with other types of myeloproliferative disorders or myelodysplastic syndromes.
  • MS is a rare disease, estimated to comprise between 2 to approximately 14% of acute myeloid leukemia.
  • On the other hand, 95% of cases of CML have characteristic t (9;22) cytogenetic abnormality and BCR/ABL fusion gene at diagnosis.

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283861.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement